<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5037827</article-id><article-id pub-id-type="doi">10.3390/ijms17091555</article-id><article-id pub-id-type="publisher-id">ijms-17-01555</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tebani</surname><given-names>Abdellah</given-names></name><xref ref-type="aff" rid="af1-ijms-17-01555">1</xref><xref ref-type="aff" rid="af2-ijms-17-01555">2</xref><xref ref-type="aff" rid="af3-ijms-17-01555">3</xref></contrib><contrib contrib-type="author"><name><surname>Afonso</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="af3-ijms-17-01555">3</xref></contrib><contrib contrib-type="author"><name><surname>Marret</surname><given-names>St&#x000e9;phane</given-names></name><xref ref-type="aff" rid="af2-ijms-17-01555">2</xref><xref ref-type="aff" rid="af4-ijms-17-01555">4</xref></contrib><contrib contrib-type="author"><name><surname>Bekri</surname><given-names>Soumeya</given-names></name><xref ref-type="aff" rid="af1-ijms-17-01555">1</xref><xref ref-type="aff" rid="af2-ijms-17-01555">2</xref><xref rid="c1-ijms-17-01555" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cho</surname><given-names>William Chi-shing</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-17-01555"><label>1</label>Department of Metabolic Biochemistry, Rouen University Hospital, 76031 Rouen, France; <email>abdellah.tebani@chu-rouen.fr</email></aff><aff id="af2-ijms-17-01555"><label>2</label>Normandie University, UNIROUEN, INSERM, CHU Rouen, Laboratoire NeoVasc ERI28, 76000 Rouen, France; <email>stephane.marret@chu-rouen.fr</email></aff><aff id="af3-ijms-17-01555"><label>3</label>Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France; <email>carlos.afonso@univ-rouen.fr</email></aff><aff id="af4-ijms-17-01555"><label>4</label>Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031 Rouen, France</aff><author-notes><corresp id="c1-ijms-17-01555"><label>*</label>Correspondence: <email>soumeya.bekri@chu-rouen.fr</email>; Tel.: +33-2-32-88-81-24; Fax: +33-2-32-88-83-41</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2016</year></pub-date><volume>17</volume><issue>9</issue><elocation-id>1555</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>07</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2016</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The rise of technologies that simultaneously measure thousands of data points represents the heart of systems biology. These technologies have had a huge impact on the discovery of next-generation diagnostics, biomarkers, and drugs in the precision medicine era. Systems biology aims to achieve systemic exploration of complex interactions in biological systems. Driven by high-throughput omics technologies and the computational surge, it enables multi-scale and insightful overviews of cells, organisms, and populations. Precision medicine capitalizes on these conceptual and technological advancements and stands on two main pillars: data generation and data modeling. High-throughput omics technologies allow the retrieval of comprehensive and holistic biological information, whereas computational capabilities enable high-dimensional data modeling and, therefore, accessible and user-friendly visualization. Furthermore, bioinformatics has enabled comprehensive multi-omics and clinical data integration for insightful interpretation. Despite their promise, the translation of these technologies into clinically actionable tools has been slow. In this review, we present state-of-the-art multi-omics data analysis strategies in a clinical context. The challenges of omics-based biomarker translation are discussed. Perspectives regarding the use of multi-omics approaches for inborn errors of metabolism (IEM) are presented by introducing a new paradigm shift in addressing IEM investigations in the post-genomic era.</p></abstract><kwd-group><kwd>omics</kwd><kwd>next-generation sequencing</kwd><kwd>mass spectrometry</kwd><kwd>machine learning</kwd><kwd>chemometrics</kwd><kwd>data integration</kwd><kwd>bioinformatics</kwd><kwd>biomarkers</kwd><kwd>inborn errors of metabolism</kwd><kwd>precision medicine</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-17-01555"><title>1. Introduction</title><p>Precision medicine (PM) is a disruptive concept that takes into account both individual variability and population characteristics to provide personalized care; this approach widens biological knowledge and explores the great diversity of individuals [<xref rid="B1-ijms-17-01555" ref-type="bibr">1</xref>]. PM comprises the customization of healthcare for an individual on the basis of measurements obtained at the individual level. However, it also uses the data and learning retrieved from the rest of the population. Hence, PM relies on both biological individuality and population knowledge to provide tailored healthcare. One of the goals of PM is to use the ever-growing understanding of biology to provide patients with accurate and personalized interventions. All PM strategies include the use of decision-making processes based on biomarker-driven approaches. Genes, gene expression products (i.e., transcripts and proteins), and metabolites are the main biomarker families. Given this molecular diversity of biomarkers, the increase in high-throughput omics technologies offers an amazing opportunity to capture the whole picture of biological systems in a hypothesis-free and unbiased mode. These global strategies are, conceptually, clearly disruptive compared to the current ones, which are mainly hypothesis-driven and, thus, intrinsically reductionist. Holistic investigative methods need to be applied to multiple levels of biological information to deeply understand disease processes.</p><p>The prediction of normal and pathological states in patients is based on a dynamic understanding of gene&#x02013;environment interactions on individual and population scales [<xref rid="B2-ijms-17-01555" ref-type="bibr">2</xref>]. The new concept of systems medicine relies on global and integrative approaches for patient care. A biological system can be fully understood only if the space and time scales are considered. <xref ref-type="fig" rid="ijms-17-01555-f001">Figure 1</xref> gives an overview of the multi-scale perspective of systems medicine.</p><p>For centuries, biological sciences independently addressed the different parts of life systems and physicians viewed and addressed diseases. Global information retrieval allows contextual pathophysiology understanding of the disease for better diagnosis and treatment [<xref rid="B2-ijms-17-01555" ref-type="bibr">2</xref>,<xref rid="B3-ijms-17-01555" ref-type="bibr">3</xref>]. Structure, organization, and function descriptions should be considered for a complete understanding of a given biological system. The structure involves basic biomolecules (genes, gene expression products, proteins, and metabolites). The topological connections between these molecules define the organization. The function reflects how the system evolves with regard to metabolic fluxes and environmental stimuli [<xref rid="B4-ijms-17-01555" ref-type="bibr">4</xref>,<xref rid="B5-ijms-17-01555" ref-type="bibr">5</xref>].</p><p>Inborn errors of metabolism (IEM) are an appealing model for systems medicine because the disrupted pathways underlying these diseases have been described at least to some extent. IEM clinical presentations are often non-specific; therefore, appropriate laboratory tests are pivotal for making a diagnosis [<xref rid="B6-ijms-17-01555" ref-type="bibr">6</xref>]. However, the widespread routine laboratory diagnosis strategies are mainly represented by sequential investigation assays. This approach is slow and lacks an integrated overview of the generated data. For faster and effective IEM screening and diagnosis, a paradigm shift in investigation strategies is urgently needed. A part of the answer may be found in the new field of systems medicine that capitalizes on omics surge, bioinformatics, and computational advancements to translate the huge amount of data generated by high-throughput omics technologies into effective clinically actionable tools to aid medical decision-making.</p><p>In this review, omics technologies that allow holistic biological information retrieval are described. Furthermore, the huge potential of multi-omics data integration strategies within the clinical context is described, as is its role as a key driver for the clinical actionability of omics-based biomarkers. Challenges facing their clinical implementation are then discussed. There is a focus on the relevance of the use of these strategies in IEM.</p></sec><sec id="sec2-ijms-17-01555"><title>2. Omics Revolution in Translational and Clinical Contexts</title><p>Since the discovery of the DNA structure [<xref rid="B7-ijms-17-01555" ref-type="bibr">7</xref>], great advances have been made in understanding genome complexity; these advances have led to sequencing the whole human genome using international endeavors such as the Human Genome Project [<xref rid="B8-ijms-17-01555" ref-type="bibr">8</xref>]. Genomics approaches have been widely adopted in biomedical research and have successfully identified the genes and genetic loci involved in the development of human diseases [<xref rid="B9-ijms-17-01555" ref-type="bibr">9</xref>,<xref rid="B10-ijms-17-01555" ref-type="bibr">10</xref>,<xref rid="B11-ijms-17-01555" ref-type="bibr">11</xref>]. These findings revealed the complexity of biological systems and provided insights for new approaches to disease diagnosis, treatment, and prevention [<xref rid="B12-ijms-17-01555" ref-type="bibr">12</xref>,<xref rid="B13-ijms-17-01555" ref-type="bibr">13</xref>,<xref rid="B14-ijms-17-01555" ref-type="bibr">14</xref>,<xref rid="B15-ijms-17-01555" ref-type="bibr">15</xref>]. Additionally, other high-throughput omics technologies have been developed to measure other biomolecules, such as epigenomics for epigenetic markers, proteomics for proteins and peptides, and metabolomics for low-molecular-weight metabolites. High-throughput analytical methods allow us to study a large number of omics markers simultaneously. In many ways, omics association studies are similar because they search for omics biomarkers connected with phenotype by unbiased ome-wide screening. Given the uneven maturity of the different omics technologies, genomics seems to be the closest next-generation sequencing (NGS)-based technology introduced into the clinic compared to transcriptomics and epigenomics, which are still promising. Regarding mass spectrometry (MS)-based omics, metabolomics seems to be closer than proteomics to being introduced into clinical practice because metabolite analyses using MS are already routinely adopted in clinical laboratories for drug monitoring and IEM screening. In this review, we mainly focus on mature omics technologies that are actively involved in clinical practice to achieve the promise of PM. However, an overview is also given regarding all omics methods.</p><sec id="sec2dot1-ijms-17-01555"><title>2.1. Omics Technologies</title><sec id="sec2dot1dot1-ijms-17-01555"><title>2.1.1. High-Throughput Sequencing (HTS) Technologies</title><p>Next-generation sequencing (NGS) techniques using a massive parallel sequencing strategy have profoundly changed the clinical genomic landscape. HTS techniques can be classified according to their applications for investigating genomes, epigenomes, or transcriptome. NGS-based strategies that could be used in medical diagnostics vary according to the size of the interrogated genome. These strategies include capturing the few protein-coding regions of a selected panel of genes (tens to hundreds), sequencing of the entire genetic code of a person, which is called whole-genome sequencing (WGS), and sequencing parts of the genome that contain exonic regions, which is called whole-exome sequencing (WES). WGS and WES are used to discover variants associated with a cell function or a disease [<xref rid="B16-ijms-17-01555" ref-type="bibr">16</xref>,<xref rid="B17-ijms-17-01555" ref-type="bibr">17</xref>,<xref rid="B18-ijms-17-01555" ref-type="bibr">18</xref>]. However, NGS-based transcriptome analysis (RNA-seq) [<xref rid="B19-ijms-17-01555" ref-type="bibr">19</xref>] entails quantitative gene expression profiling, whereas epigenomic methods focus on chromatin structure [<xref rid="B20-ijms-17-01555" ref-type="bibr">20</xref>].</p><sec><title>Genomics</title><p>The genome is the complete set of DNA of an organism. This genetic material is mainly found in the nucleus of the human cell (nuclear DNA). Mitochondria contain their own genome (mitochondrial DNA). Fredrick Sanger described the chain-termination strategy to replicate a nucleotide sequence of a DNA fragment (500&#x02013;1000 bases) [<xref rid="B21-ijms-17-01555" ref-type="bibr">21</xref>]. Sanger used chemically modified nucleotide bases and radioactive labeling, along with DNA polymerase, primers, chain-terminating nucleotides, and electrophoresis. Since then, sequencing chemistries evolved using fluorophore-labeled dideoxynucleotides and thermostable DNA polymerases allowed cycled sequencing. Electrophoresis automation and laser detection enhanced the sensitivity of this method [<xref rid="B22-ijms-17-01555" ref-type="bibr">22</xref>,<xref rid="B23-ijms-17-01555" ref-type="bibr">23</xref>,<xref rid="B24-ijms-17-01555" ref-type="bibr">24</xref>]. The replicated DNA fragments produce signals (electropherogram peaks) related to the nucleotide sequence. Thereafter, these reads undergo an alignment step with a reference genome to identify variants and define their genomic origin. Of note, the Sanger method is still considered the standard method for DNA sequencing accuracy of approximately 1 in 10,000 bases. The first human genome sequence was achieved in 2001 [<xref rid="B25-ijms-17-01555" ref-type="bibr">25</xref>,<xref rid="B26-ijms-17-01555" ref-type="bibr">26</xref>]. The genome sequences of several model organisms were determined soon thereafter. These endeavors were accomplished with Sanger DNA sequencing, which involves high costs and low throughput. These drawbacks limited the potential of DNA sequencing for healthcare translation. Several HTS technologies were developed soon after the release of the human genome sequence [<xref rid="B27-ijms-17-01555" ref-type="bibr">27</xref>] and high-throughput analysis became widely available for genomics. NGS-based platforms provide the ability to replicate, in parallel, many overlapping short DNA fragments (50&#x02013;500) derived from already prepared libraries. There are different innovative approaches to the special separation of fragments on arrays or beads [<xref rid="B8-ijms-17-01555" ref-type="bibr">8</xref>,<xref rid="B28-ijms-17-01555" ref-type="bibr">28</xref>,<xref rid="B29-ijms-17-01555" ref-type="bibr">29</xref>]. Simultaneous DNA replication of each fragment during the reaction cycles produces billions of short elongations of the DNA sequence. These short stretches are called reads. Hence, each base is synthesized several times. The lowest number of times that each base being monitored is incorporated into an overlapping fragment is called depth of coverage. At the end of the cycle, all the short reads are assembled according to a reference sequence that allows for reconstruction of the original sequence, ranging from a small exon to an entire genome. Innovative high-throughput NGS-based methods have the ability to conserve the genome information and the redundancy of the sequenced genome through their depth of coverage. Different commercial HTS platforms exist. These platforms differ mainly in their sequencing strategies (ligation versus synthesis), amplification by polymerase chain reaction (PCR) of the DNA fragments (flow cell bridge PCR versus bead emulsion PCR), and finally in their adopted targeted approach (PCR amplification versus hybrid capture) [<xref rid="B8-ijms-17-01555" ref-type="bibr">8</xref>].</p><p>HTS are powerful technologies for personal genome and transcriptome sequencing [<xref rid="B8-ijms-17-01555" ref-type="bibr">8</xref>]. Variants can only be interpreted with a good clinical history, family history, and physical examination. These preliminary steps allow physicians to assess whether there are similar or related phenotypes in other family members; if so, then the inheritance pattern can be evaluated. However, clinical validity is the most challenging aspect of NGS. According to the size of the interrogated genomic information, three strategies could be used for diagnosis purposes. Targeted gene sequencing panels are useful tools for analyzing specific genes in a given clinical condition and are widely used in current clinical practice [<xref rid="B14-ijms-17-01555" ref-type="bibr">14</xref>,<xref rid="B15-ijms-17-01555" ref-type="bibr">15</xref>]. WES focuses on the more functional and informative part of the genome and is being adopted for genetic studies of IEM for gene identification and clinical diagnosis [<xref rid="B10-ijms-17-01555" ref-type="bibr">10</xref>,<xref rid="B11-ijms-17-01555" ref-type="bibr">11</xref>,<xref rid="B30-ijms-17-01555" ref-type="bibr">30</xref>,<xref rid="B31-ijms-17-01555" ref-type="bibr">31</xref>]. This approach might shortly replace targeted approaches. WGS provides a unique window to investigate genetic or somatic variations, thus leading to new avenues for exploration of normal and disease phenotypes. However, the inherent data management and interpretation issues hamper its clinical implementation [<xref rid="B32-ijms-17-01555" ref-type="bibr">32</xref>]. From a clinical perspective, comparing different genomic diagnostics approaches is of great interest but requires standard and adopted metrics [<xref rid="B33-ijms-17-01555" ref-type="bibr">33</xref>]. Sanger sequencing is the gold standard and allows confident calling of genotypes. Because non-inferiority is a prerequisite for clinical adoption of any new medical innovation, Goldfeder et al. recently proposed an interesting metric to quantify the clinical grade reporting standard of sequencing technologies [<xref rid="B34-ijms-17-01555" ref-type="bibr">34</xref>].</p></sec><sec><title>Epigenomics</title><p>Chemical modifications of DNA, histones, non-histone chromatin proteins, and nuclear RNA define the epigenome. These changes affect gene expression without altering the base sequence. Epigenetics usually refers to the structural adaptation of chromosomal regions. These epigenetic marks may be transient or inherited through cell division [<xref rid="B35-ijms-17-01555" ref-type="bibr">35</xref>]. They are due to environmental exposures at various developmental stages throughout the life span [<xref rid="B36-ijms-17-01555" ref-type="bibr">36</xref>]. The four main actors of epigenetic machinery include DNA methylation, histone modification, microRNA (miRNA) expression and processing, and chromatin condensation [<xref rid="B37-ijms-17-01555" ref-type="bibr">37</xref>,<xref rid="B38-ijms-17-01555" ref-type="bibr">38</xref>]. Epigenomic modifications depend on spatial and time-related factors. Therefore, they can be tissue-specific in response to environmental or disease-related modifiers. These modifications could regulate gene expression and, thus, affect cell homeostasis. Comprehensive mapping of epigenetic makeup in many cell types and tissues has been reported [<xref rid="B39-ijms-17-01555" ref-type="bibr">39</xref>]. Different strategies have been developed to assess the epigenome [<xref rid="B20-ijms-17-01555" ref-type="bibr">20</xref>]. Epigenomics methods generally focus on chromatin structure and include histone modification ChIP-seq (chromatin immunoprecipitation sequencing), thus allowing the identification of DNA-associated protein-binding sites [<xref rid="B40-ijms-17-01555" ref-type="bibr">40</xref>]. DNase-seq combines DNase I digestion of chromatin with HTS to identify regulatory regions of the genome [<xref rid="B41-ijms-17-01555" ref-type="bibr">41</xref>]. DNA methylation [<xref rid="B42-ijms-17-01555" ref-type="bibr">42</xref>] and ATAC-seq (assay for transposase-accessible chromatin sequencing) allow the mapping of chromatin accessibility genome-wide [<xref rid="B43-ijms-17-01555" ref-type="bibr">43</xref>]. For more technical details, the reader may refer to a recent review [<xref rid="B44-ijms-17-01555" ref-type="bibr">44</xref>]. Recently, an epigenome-wide study suggested that interindividual variations in high-density lipoprotein (HDL) particle metabolism rely on epigenome modifications [<xref rid="B45-ijms-17-01555" ref-type="bibr">45</xref>].</p></sec><sec><title>Transcriptomics</title><p>The gene expression pattern in a cell/tissue can broadly reflect its functional state. The transcriptome is the complete set of RNA transcripts, including ribosomal RNA (rRNA), messenger RNA (mRNA) that represents only 1.5 to 2 percent of the transcriptome, transfer RNA (tRNA), miRNA, and other non-coding RNA (ncRNA). Quantitative analyses of the transcriptome can be performed with either microarrays (Chips) or RNA sequencing (RNAseq). Microarrays are based on specific hybridization of RNA transcripts to DNA probes, and HTS-based expression profiling by RNA-seq allows comprehensive qualitative and quantitative mapping of all transcripts [<xref rid="B19-ijms-17-01555" ref-type="bibr">19</xref>]. The massively parallel capabilities of HTS have dramatically widened the transcriptional landscape with small quantities of total RNA [<xref rid="B46-ijms-17-01555" ref-type="bibr">46</xref>]. Transcriptome-based studies have been applied to some IEM such as McArdle disease [<xref rid="B47-ijms-17-01555" ref-type="bibr">47</xref>], Hunter disease [<xref rid="B48-ijms-17-01555" ref-type="bibr">48</xref>], lysinuric protein intolerance [<xref rid="B49-ijms-17-01555" ref-type="bibr">49</xref>], Lesch&#x02013;Nyhan disease [<xref rid="B50-ijms-17-01555" ref-type="bibr">50</xref>], and Niemann&#x02013;Pick C disease [<xref rid="B51-ijms-17-01555" ref-type="bibr">51</xref>].</p></sec></sec><sec id="sec2dot1dot2-ijms-17-01555"><title>2.1.2. Mass Spectrometry-Based Omics</title><p>MS analyzers are instruments that weigh molecules and separate them according to their mass-to-charge ratios. There are several MS analyzers with different analytical technologies and, thus, various performance levels regarding resolution, accuracy, throughput and chemical coverage. MS analysis could be semi-quantitative in an untargeted fashion using high-resolution MS instruments or quantitative through targeted analysis using tandem MS [<xref rid="B52-ijms-17-01555" ref-type="bibr">52</xref>,<xref rid="B53-ijms-17-01555" ref-type="bibr">53</xref>,<xref rid="B54-ijms-17-01555" ref-type="bibr">54</xref>]. MS instruments could be combined with separation methods such as liquid or gas chromatography, capillary electrophoresis, or ion mobility. These combinations aim to enhance the dynamic range, sensitivity, specificity, and chemical coverage [<xref rid="B55-ijms-17-01555" ref-type="bibr">55</xref>,<xref rid="B56-ijms-17-01555" ref-type="bibr">56</xref>]. Given the chemical diversity of proteins and metabolites and the high sensitivity of this technology, MS has proven its superiority in metabolomics and proteomics.</p><sec><title>Proteomics</title><p>The proteome consists of all the proteins expressed by a biological system [<xref rid="B57-ijms-17-01555" ref-type="bibr">57</xref>]. Posttranslational modifications rely on a highly specialized enzymatic arsenal specific to each cellular type, which leads to the generation of different proteomes from the same genome. These modifications add layers in proteome complexity and, thus, broaden their functionalities [<xref rid="B58-ijms-17-01555" ref-type="bibr">58</xref>]. Hence, proteins exhibit different conformation, localization, and interactions depending on space and time factors. The development of proteomics assays is triggered by these complexity challenges. The proteome can mainly be analyzed using MS or protein microarrays [<xref rid="B53-ijms-17-01555" ref-type="bibr">53</xref>,<xref rid="B59-ijms-17-01555" ref-type="bibr">59</xref>]. However, MS and protein separation allow rapid and accurate detection of hundreds of human proteins and peptides from a small amount of body fluid or tissue [<xref rid="B59-ijms-17-01555" ref-type="bibr">59</xref>,<xref rid="B60-ijms-17-01555" ref-type="bibr">60</xref>,<xref rid="B61-ijms-17-01555" ref-type="bibr">61</xref>]. Recent studies showed promising results using proteome analysis to explore cystinuria [<xref rid="B62-ijms-17-01555" ref-type="bibr">62</xref>], mucopolysaccharidoses [<xref rid="B63-ijms-17-01555" ref-type="bibr">63</xref>], and liver mitochondrial functions [<xref rid="B64-ijms-17-01555" ref-type="bibr">64</xref>]. Despite increasing analytical performances, proteomics has not been used in routine clinical laboratory practice [<xref rid="B65-ijms-17-01555" ref-type="bibr">65</xref>].</p></sec><sec><title>Metabolomics</title><p>The idea behind metabolomics or metabolic profiling has been empirically used in the past; for example, urine organoleptic characteristics (taste, odor, or color) aided in the diagnosis of medical conditions [<xref rid="B66-ijms-17-01555" ref-type="bibr">66</xref>]. The metabolome is defined as the set of metabolites present in a given biological system, fluid, cell, or tissue at a given time [<xref rid="B67-ijms-17-01555" ref-type="bibr">67</xref>]. Metabolomics is an omics approach based on biochemical characterizations of the metabolites and their fluctuations related to internal (genetic) and external factors (environment) [<xref rid="B68-ijms-17-01555" ref-type="bibr">68</xref>]. The metabolomics approach has been applied in many disease studies [<xref rid="B69-ijms-17-01555" ref-type="bibr">69</xref>,<xref rid="B70-ijms-17-01555" ref-type="bibr">70</xref>]. MS and nuclear magnetic resonance (NMR) are the main analytical techniques used in metabolomics [<xref rid="B71-ijms-17-01555" ref-type="bibr">71</xref>]. However, MS is already adopted in clinical laboratories. New advances in analytical technologies such as ion mobility spectrometry (IMS) combined with high-resolution MS have allowed better coverage of the metabolome [<xref rid="B56-ijms-17-01555" ref-type="bibr">56</xref>]. Because IEM are related to metabolism disruption, metabolomics is indicated in assessing these diseases. The future of IEM diagnoses relies on simultaneous quantitative metabolic profiling of many metabolites in biological fluids. Targeted MS-based metabolomics is already widely used and implemented in IEM newborn screening national programs worldwide [<xref rid="B72-ijms-17-01555" ref-type="bibr">72</xref>]. Untargeted approaches have also been tested and have shown promising results [<xref rid="B73-ijms-17-01555" ref-type="bibr">73</xref>,<xref rid="B74-ijms-17-01555" ref-type="bibr">74</xref>]. An integrated strategy for IEM assessment using both targeted and untargeted approaches has been recently proposed by Miller et al. This strategy provides useful and actionable diagnostic information for IEM. The authors have successfully diagnosed 21 IEM disorders using plasma metabolite measurements through metabolomics [<xref rid="B75-ijms-17-01555" ref-type="bibr">75</xref>]. Aygen et al. performed a multi-center clinical study in 14 clinical centers in Turkey using NMR-based platforms. The urine samples of 989 neonates were analyzed. A set of specific metabolites that varies in patients compared with healthy individuals was characterized and predictive models were developed. Furthermore, a reference NMR database has been built [<xref rid="B74-ijms-17-01555" ref-type="bibr">74</xref>]. For a deeper overview of the potential of metabolomics in IEM investigations, refer to a recent comprehensive review reporting underlying metabolic profiling technologies with limits and advantages and their applications in IEM [<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>].</p></sec></sec><sec id="sec2dot1dot3-ijms-17-01555"><title>2.1.3. Phenomics</title><p>Phenome is a term that describes the measurable physical and chemical outcomes of the interactions between genes and the environment that are experienced by individuals and influence their phenotypes [<xref rid="B77-ijms-17-01555" ref-type="bibr">77</xref>]. Hence, phenotypes could be retrieved through precise, quantitative analysis [<xref rid="B78-ijms-17-01555" ref-type="bibr">78</xref>]. Phenomics, which is a branch of science that explores the basis of how our genes respond to environmental changes, is an emerging and powerful approach to revealing important human attributes at the molecular level. It aims to explain how we adapt and why we are affected by diseases [<xref rid="B79-ijms-17-01555" ref-type="bibr">79</xref>]. In other words, phenomics approaches capture our personalized experience with our environment [<xref rid="B80-ijms-17-01555" ref-type="bibr">80</xref>,<xref rid="B81-ijms-17-01555" ref-type="bibr">81</xref>,<xref rid="B82-ijms-17-01555" ref-type="bibr">82</xref>,<xref rid="B83-ijms-17-01555" ref-type="bibr">83</xref>,<xref rid="B84-ijms-17-01555" ref-type="bibr">84</xref>].</p><p>Two main pillars build phenomics: deep phenotyping (DP) and phenomics analysis (PA). DP refers to a strategic and comprehensive approach to data acquisition that includes clinical assessment, laboratory analyses, pathology, and imaging. PA involves the evaluation of patterns and relationships between individuals with related phenotypes and/or between genotype&#x02013;phenotype associations. PA relies on both clinical data and high-dimensional data integration [<xref rid="B85-ijms-17-01555" ref-type="bibr">85</xref>], analysis, and visualization [<xref rid="B81-ijms-17-01555" ref-type="bibr">81</xref>,<xref rid="B86-ijms-17-01555" ref-type="bibr">86</xref>,<xref rid="B87-ijms-17-01555" ref-type="bibr">87</xref>].</p><p>In a recent work, Kochinke et al. provided a curated database of 746 currently known genes involved in intellectual disability (ID). The genes were classified according to ID-associated clinical features. This work allowed systematic insights into the clinical and molecular landscapes of ID disorders [<xref rid="B88-ijms-17-01555" ref-type="bibr">88</xref>]. Kim et al. introduced the integrative phenotyping framework (iPF) for disease subtype identification. This solution allows accessible visualization of multi-omics data following effective dimension reduction. The strategy has been successfully applied to chronic obstructive lung disease (COPD) [<xref rid="B89-ijms-17-01555" ref-type="bibr">89</xref>]. The Monarch initiative is an impressive global endeavor that provides computational tools for genotype&#x02013;phenotype analysis, genomic diagnostics, and PM across broad areas of disease. Thus, the Monarch initiative illustrates the importance of phenomics [<xref rid="B90-ijms-17-01555" ref-type="bibr">90</xref>].</p><p>For more details, the reader may refer to a recent review reporting state-of-the art phenome-wide association studies [<xref rid="B79-ijms-17-01555" ref-type="bibr">79</xref>].</p></sec></sec><sec id="sec2dot2-ijms-17-01555"><title>2.2. Multi-Omics Strategies, or When the Whole Is More than the Sum of Its Parts</title><p>Although each omics technology is able to measure one family of biomolecules accurately and comprehensively, they are all limited by the functional roles of each type of molecule in a biological system. With the significant advancement of high-throughput technologies and diagnostic techniques described here, the molecular basis of many disorders has been unveiled and their integrative consideration could help solve this issue. However, translation of a patient-specific molecular mechanism into personalized clinical applications remains a challenging task that requires integration of multi-dimensional molecular and clinical data into patient-centric models. For example, family history, clinical history, and physical examination are mandatory for the interpretation of variants and laboratory results. However, in NGS, reporting the result is a very tricky task. NGS test accuracy is at its best when the considered variant in a given gene has been previously associated with the patient&#x02019;s condition and when a conclusive functional test has revealed the gene&#x02019;s function abnormalities. Furthermore, few functional studies are available regarding the biological effect of individual variants. This largely impedes effective and comprehensive interpretation of NGS data. In this regard, PM combining multilayer molecular information and specific clinical phenotypes for a given patient may be an answer to this limit [<xref rid="B1-ijms-17-01555" ref-type="bibr">1</xref>]. Applying the PM concept to omics and clinical data is a challenging and exciting task. This integrative view of disease modeling is an emerging knowledge-based paradigm in translational and clinical research that capitalizes on the ever-growing power of computational methods to collect, store, integrate, model, and interpret curated disease information across multi-scale biology from molecules to phenotypes [<xref rid="B85-ijms-17-01555" ref-type="bibr">85</xref>,<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>]. With the tremendous amount of available biological and clinical data, the development of appropriate data mining tools is mandatory to extract the hidden information, thereby allowing its translation into actionable clinical tools [<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>,<xref rid="B92-ijms-17-01555" ref-type="bibr">92</xref>]. As technologies keep evolving and datasets grow in volume, velocity, and variety in the big data era, a strong informatics infrastructure will be essential to embrace the PM promise of improved healthcare derived from personal data. Different computational solutions using machine learning and dimension reduction methods have been developed for omics integration [<xref rid="B93-ijms-17-01555" ref-type="bibr">93</xref>]. Recent studies have shown the potential of multi-omics studies to provide insightful biological inferences [<xref rid="B64-ijms-17-01555" ref-type="bibr">64</xref>,<xref rid="B94-ijms-17-01555" ref-type="bibr">94</xref>,<xref rid="B95-ijms-17-01555" ref-type="bibr">95</xref>,<xref rid="B96-ijms-17-01555" ref-type="bibr">96</xref>,<xref rid="B97-ijms-17-01555" ref-type="bibr">97</xref>,<xref rid="B98-ijms-17-01555" ref-type="bibr">98</xref>,<xref rid="B99-ijms-17-01555" ref-type="bibr">99</xref>] and to help determine definitive diagnoses in the IEM field [<xref rid="B10-ijms-17-01555" ref-type="bibr">10</xref>,<xref rid="B11-ijms-17-01555" ref-type="bibr">11</xref>].</p></sec><sec id="sec2dot3-ijms-17-01555"><title>2.3. Issues and Limitations of Omics Analysis</title><sec id="sec2dot3dot1-ijms-17-01555"><title>2.3.1. Technical Limitations</title><sec><title>Experimental and Analytical Noise</title><p>Reproducibility and repeatability are prerequisites for obtaining consistent results [<xref rid="B100-ijms-17-01555" ref-type="bibr">100</xref>]. These important validation steps are hampered by the so-called batch effects. In addition, this drawback can be an important confounder in association studies and potentially causes spurious associations unrelated to the outcomes of interest. Multiple technical platforms from different manufacturers are usually available for the same type of omics profiling. For example, multiple versions of microarray and sequencing platforms are available for genomics, transcriptomics, and epigenomics association studies. They usually have different coverage of the sequenced regions [<xref rid="B44-ijms-17-01555" ref-type="bibr">44</xref>]. MS platforms for proteomics and metabolomics have different sensitivities and chemical space coverage [<xref rid="B61-ijms-17-01555" ref-type="bibr">61</xref>,<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. This is due to the differences in MS analyzer technology in terms of ionization method, resolution power, measurement accuracy, multi-dimensional separation, scan speed, dynamic range, and analysis throughput [<xref rid="B55-ijms-17-01555" ref-type="bibr">55</xref>,<xref rid="B56-ijms-17-01555" ref-type="bibr">56</xref>,<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. Such technical heterogeneity often makes meta-analysis and data fusion of different omics studies very challenging. Batch effects issues can be handled by using harmonized Standard Operating Procedures (SOPs) [<xref rid="B101-ijms-17-01555" ref-type="bibr">101</xref>,<xref rid="B102-ijms-17-01555" ref-type="bibr">102</xref>,<xref rid="B103-ijms-17-01555" ref-type="bibr">103</xref>,<xref rid="B104-ijms-17-01555" ref-type="bibr">104</xref>]. Furthermore, using standard quality control (QC) processes and metrics to normalize intra-laboratory and inter-laboratory omics measurement variations [<xref rid="B105-ijms-17-01555" ref-type="bibr">105</xref>,<xref rid="B106-ijms-17-01555" ref-type="bibr">106</xref>] and applying consistent statistical correction methods [<xref rid="B107-ijms-17-01555" ref-type="bibr">107</xref>,<xref rid="B108-ijms-17-01555" ref-type="bibr">108</xref>,<xref rid="B109-ijms-17-01555" ref-type="bibr">109</xref>] and appropriate computational tools [<xref rid="B110-ijms-17-01555" ref-type="bibr">110</xref>] can address some technical variation issues.</p></sec><sec><title>Analytical Accuracy and Clinical Relevance</title><p>Historically, genomics has tightly evolved along with reference sequence GRCh38 [<xref rid="B111-ijms-17-01555" ref-type="bibr">111</xref>]. The genome contains approximately 20,000 protein-coding genes, and these vary enormously, spanning from eight base pairs (a transfer RNA) to millions of base pairs. For a given gene, the exon number spans from one to hundreds. Furthermore, a gene&#x02019;s GC richness is a great challenge, especially for capture chemistry-based targeted sequencing. This great genome complexity presents challenges for NGS sequencing strategies regarding accuracy, which is the mandatory prerequisite for clinical implementation. For example, given the intrinsic short-reads sequencing strategies of HTS, simple repeats that are shorter than the read could be determined with NGS. However, if the read length is shorter than the repeat stretch, then the size of the repeated region is difficult to define [<xref rid="B112-ijms-17-01555" ref-type="bibr">112</xref>]. Another clinically relevant challenge to using short reads is the lack of phase information, which is the parental chromosomal origin. The characterization of compound heterozygosity (two identified variants in the same gene) is challenging and, thus, illustrates this limitation. A variant-calling algorithm solution has been developed to handle such issues [<xref rid="B113-ijms-17-01555" ref-type="bibr">113</xref>]. To solve some of these challenges, long-read sequencing strategies such as using either longer molecule barcoding fragments combined with short-read sequencing and in silico assembly [<xref rid="B114-ijms-17-01555" ref-type="bibr">114</xref>] or longer molecule direct sequencing may be of interest [<xref rid="B115-ijms-17-01555" ref-type="bibr">115</xref>]. Such sequencing strategies may provide a more accurate view of the genome. Chaisson et al. provided seminal evidence for the utility of long-read sequencing to generate high-quality reference genomes. The authors closed euchromatic gaps in the GRCh37 human reference genome using long-read sequencing [<xref rid="B115-ijms-17-01555" ref-type="bibr">115</xref>]. Another major drawback of existing NGS strategies is the need for time-consuming library preparation and DNA enrichment. More automation of this step would enhance the workload and turnover and dramatically change the adoption of NGS into the clinical environment, which requires a high standard of accuracy and rapid reporting of results. The use of nanopores is a promising technology that could overcome this limitation by directly sequencing DNA fragments by passing through nanopores using either nanophotonic chambers [<xref rid="B116-ijms-17-01555" ref-type="bibr">116</xref>] or a protein nanopore [<xref rid="B117-ijms-17-01555" ref-type="bibr">117</xref>].</p><p>Regarding MS-based omics, there are still great challenges regarding their widespread use in the clinical environment. For metabolomics, the great drawback is still metabolite identification, particularly for untargeted approaches [<xref rid="B118-ijms-17-01555" ref-type="bibr">118</xref>]. Accurate curated spectral repositories are essential to their clinical adoption and compliance with regulatory issues. Furthermore, harmonization of data reporting and data visualization in clinically accessible formats limits their clinical implementations [<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. Proteomic analysis is technically challenging and has major drawbacks due to splice variants and post-translational modifications of divers. The post-translational modifications interfere with DNA and RNA measurements of protein level predictions [<xref rid="B119-ijms-17-01555" ref-type="bibr">119</xref>,<xref rid="B120-ijms-17-01555" ref-type="bibr">120</xref>]. Better proteomic measurements require unbiased identification and quantification of proteins by direct measurements using methods analyzing their unique structure, mass, and charge with high specificity [<xref rid="B106-ijms-17-01555" ref-type="bibr">106</xref>,<xref rid="B121-ijms-17-01555" ref-type="bibr">121</xref>,<xref rid="B122-ijms-17-01555" ref-type="bibr">122</xref>]. Furthermore, subtle changes in the detection of low-abundance proteins, which are often important in early-stage disease screening, might be affected by MS sensitivity limits. To overcome this limitation, different approaches have been proposed. One approach is immunocapture enrichment of low-abundance proteins prior to their MS detection [<xref rid="B123-ijms-17-01555" ref-type="bibr">123</xref>] at the expense of additional steps in the analytical process, which may affect the throughput. The MS-based omics community is aware of these limitations and actively strives to overcome them [<xref rid="B54-ijms-17-01555" ref-type="bibr">54</xref>,<xref rid="B104-ijms-17-01555" ref-type="bibr">104</xref>,<xref rid="B124-ijms-17-01555" ref-type="bibr">124</xref>].</p></sec><sec><title>Omics Informatics Pipelines in the Clinical Environment</title><p>A bioinformatics pipeline is a sequential series of computationally complex data analysis processes spanning from raw data retrieval to final results output. The series includes processing, data analysis, and interrogation of reference databases. Two main pipelines are discussed here, NGS and MS-based pipelines. <xref ref-type="fig" rid="ijms-17-01555-f002">Figure 2</xref> represents a schematic overview of both pipelines.</p></sec><sec><title>NGS Informatics Pipeline</title><p>Millions of reads are generated by most common NGS platforms using short reads that overlap either the whole genome (WGS) or a specific region (targeted sequencing). An NGS pipeline includes platform-specific software to generate the sequence derived from the primary instrument signal; this step is called base calling. Subsequently, alignment is performed against a reference human genome sequence of the overlapping reads. Several alignment algorithms have been developed with different performance results regarding sequence variation detection [<xref rid="B125-ijms-17-01555" ref-type="bibr">125</xref>,<xref rid="B126-ijms-17-01555" ref-type="bibr">126</xref>]. The aligned reads are used as input files for single-nucleotide variant (SNV) detection, copy number variation (CNV), indels, and large rearrangements using open source or commercial tools. This step is called variant calling. Several variant callers are available, such as Atlas [<xref rid="B127-ijms-17-01555" ref-type="bibr">127</xref>], MuTect [<xref rid="B128-ijms-17-01555" ref-type="bibr">128</xref>], VarScan2 [<xref rid="B129-ijms-17-01555" ref-type="bibr">129</xref>], and Genome Analysis Toolkit (GATK) [<xref rid="B130-ijms-17-01555" ref-type="bibr">130</xref>]. It should be noted that these variant callers exhibit different performances depending on the platform and variant types used [<xref rid="B131-ijms-17-01555" ref-type="bibr">131</xref>]. Thus, using different variant callers for a wider coverage of variants capture is recommended. Further annotation of the detected variant is performed using clinical data, Human Genome Variation Society annotations, genome&#x02013;phenotype correlation, pathway analysis, and predicted effect (on transcription and translation). The quality and consistency of the interrogated online databases are crucial for this step. To avoid misdiagnoses, interpreting variants should be approached as a dynamic big data problem because these online databases are constantly evolving as disease knowledge evolves [<xref rid="B132-ijms-17-01555" ref-type="bibr">132</xref>]. NGS is rapidly making its way into the clinic, and its smooth integration upstream and downstream of a sequencing analysis is becoming an important issue. Informatics challenges facing the implementation of NGS in clinical environments range from data acquisition to data reporting, including data validation, data analytics, data storage, and interoperability with already existing laboratory systems and clinical informatics infrastructures. Sample tracking and workflow management logistics are the core of any clinical grade laboratory; this should also be true for NGS. However, uncommon but important downstream offline steps should be consistently tracked such as nucleic acids extraction, library preparation, sequencing runs along with upstream steps such as bioinformatics analysis, quality assurance documentation, data interpretation, and results reporting. All these steps add complexity and error sources to the workflow. To overcome interoperability problems that face in-house custom solutions, such as fragmenting of the workflow, the ideal informatics solution should be fully integrated with the laboratory information system (LIS) so it is able to track samples from order receipt to results reporting. Of note, the generated NGS data range from 10 GB for WES to 150 GB for WGS. Hence, data storage solutions need to be addressed before implementation. Data analysis challenges not only include the computationally heavy burden of the NGS bioinformatics pipeline but also involve handling the huge amount of background data related to wet laboratory steps, sample meta-data, sample processing and tracking, reports, and QC data. With all the high-dimensional data management issues, NGS clinical implementation should be approached with big data analytics solutions [<xref rid="B133-ijms-17-01555" ref-type="bibr">133</xref>].</p></sec><sec><title>Mass Spectrometry-Based Omics Informatics Pipeline</title><p>MS-based processing methods involve four main steps: (i) data acquisition; (ii) data pre-processing; (iii) data analysis using chemometrics; and (iv) identification, network, and pathway analysis [<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. Data files are acquired with proprietary software depending on each platform. Various proprietary data formats have been developed by MS manufacturers to handle MS data, but this raised sharing and processing limits between platforms. To address this problem, open formats have been developed such as netCDF, mzDATA, mzXML, and mzML [<xref rid="B134-ijms-17-01555" ref-type="bibr">134</xref>]. Data pre-processing include peak detection, peak alignment, which is a drift time correction step in separated methods (gas chromatography-MS, liquid chromatography-MS, capillary electrophoresis-MS, and ion mobility-MS). During alignment for untargeted analysis, it is crucial to match peaks corresponding to the same analytes in different samples. Subsequently, baseline correction and spectral deconvolution for visualization are performed. Depending on the algorithm used, the order of these steps might be different [<xref rid="B135-ijms-17-01555" ref-type="bibr">135</xref>]. The output of these steps is a matrix containing feature concentration or intensity across the different samples. Different output formats such as txt, csv, or an Excel spreadsheet could be used. Subsequently, before data analysis and modeling, different filters, transformations, and normalization methods could be applied to the generated matrix to handle the noise and clean the data. Then, various pattern recognition and machine learning techniques are applied to extract the important features (metabolites or proteins) for the next identification step and pathway and network analysis [<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. MS-based bioinformatics pipeline challenges are the same ones described for big data scaling and interoperability issues with Laboratory Information System (LIS) in a clinical environment. However, some limitations are specific to these platforms in particular, such as sample extraction and/or derivatization, which are offline processes that should be consistently tracked. The metabolite or protein identification steps still lack smooth and streamlined informatics solutions for direct database interrogation. From an informatics perspective, NGS seems to be much more advanced to be included in clinical practice. Therefore, many endeavors are needed to enhance MS informatics infrastructures to a clinical grade [<xref rid="B136-ijms-17-01555" ref-type="bibr">136</xref>], and some initiatives have already begun [<xref rid="B104-ijms-17-01555" ref-type="bibr">104</xref>,<xref rid="B137-ijms-17-01555" ref-type="bibr">137</xref>,<xref rid="B138-ijms-17-01555" ref-type="bibr">138</xref>].</p></sec></sec><sec id="sec2dot3dot2-ijms-17-01555"><title>2.3.2. Biological Variation</title><p>Biological variation is another source of discrepancies in omics studies. Except for genetic profiles being identical across tissues and cell types, all other omics profiles depend on sample type. Tissue and cell-type specificity lead to two important issues in multi-omics approaches: tissue and cell type selection and heterogeneity of tissues. The most accessible specimen in human samples is peripheral blood. Blood-based specimens such as plasma, serum, and leukocytes are commonly used in omics studies. Although the use of blood as a surrogate tissue is sometimes relevant, the biological relevance of blood omics profiles may not be apparent for many human diseases. Using blood-based specimens is a convenient start for searching novel disease-related biomarkers; however, using blood as a surrogate tissue requires cautious validation and interpretation to unravel disease mechanisms [<xref rid="B139-ijms-17-01555" ref-type="bibr">139</xref>,<xref rid="B140-ijms-17-01555" ref-type="bibr">140</xref>,<xref rid="B141-ijms-17-01555" ref-type="bibr">141</xref>]. Furthermore, diet, circadian rhythm, and drugs may interfere. Another issue is cell heterogeneity; a tissue sample always involves several cell types, with each having a unique omics profile. Depending on the location of a tissue sample or the individual physiological condition, the proportions of the different cell types can change substantially. Statistical methods have been developed to adjust for potential confounding effects due to cell-type heterogeneity [<xref rid="B142-ijms-17-01555" ref-type="bibr">142</xref>,<xref rid="B143-ijms-17-01555" ref-type="bibr">143</xref>,<xref rid="B144-ijms-17-01555" ref-type="bibr">144</xref>]. However, measuring the omics profile of each purified cell type is an ideal solution that could directly infer the molecular mechanism of a disease [<xref rid="B145-ijms-17-01555" ref-type="bibr">145</xref>].</p></sec></sec></sec><sec id="sec3-ijms-17-01555"><title>3. Omics and Biomarkers: From Bench to Bedside</title><sec id="sec3dot1-ijms-17-01555"><title>3.1. Definitions</title><p>A biomarker has been defined as a trait that can be objectively measured and evaluated; therefore, it can be used as an indicator of biological processes (normal versus disease) or of pharmacologic response upon a therapeutic intervention [<xref rid="B146-ijms-17-01555" ref-type="bibr">146</xref>]. The FDA defined a biomarker as a measurable endpoint that may be used as an indicator of a disease or physiological state of an organism. According to these definitions, several indicators may be included, such as imaging-based or laboratory-measured biomarkers [<xref rid="B147-ijms-17-01555" ref-type="bibr">147</xref>]. The Institute of Medicine Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials defines omics as the study of related sets of biological molecules in a comprehensive fashion. Omics-based tests are defined as &#x0201c;an assay composed of, or derived from, multiple molecular measurements and interpreted by a fully specified computational model to produce a clinically actionable result&#x0201d; [<xref rid="B148-ijms-17-01555" ref-type="bibr">148</xref>].</p></sec><sec id="sec3dot2-ijms-17-01555"><title>3.2. Biomarker Development</title><p>To be used for diagnostics or drug development, an ideal biomarker needs to be highly specific and sensitive [<xref rid="B147-ijms-17-01555" ref-type="bibr">147</xref>]. Biomarkers can be classified as pharmacodynamic by indicating the outcome of the interaction between a drug and a target [<xref rid="B149-ijms-17-01555" ref-type="bibr">149</xref>] or as prognostic/predictive by stratifying the patient population to responders and non-responders [<xref rid="B150-ijms-17-01555" ref-type="bibr">150</xref>]. Another classification that includes three types has been suggested by the Biomarkers and Surrogate End Point Working Group [<xref rid="B146-ijms-17-01555" ref-type="bibr">146</xref>,<xref rid="B151-ijms-17-01555" ref-type="bibr">151</xref>]: type 0 biomarkers indicate the natural history of disease and correlate with clinical indices, type I biomarkers track the effects of intervention associated with the drug mechanism of action, and type II biomarkers are surrogate end points that predict clinical benefit.</p><p>Biomarker development and translational strategies have four main issues that need to be addressed: analytical validity, clinical validity, clinical utility, and regulatory and ethical compliance. Analytical validity includes evidence of assay accuracy, reliability, and reproducibility. Clinical validity denotes evidence regarding the statistical association of biomarkers with the clinical outcome. Clinical utility assesses the benefit of the biomarker in terms of public health. Regulatory and ethical issues address guidelines and requirements compliance of the previous development steps with regulatory bodies and societal challenges, respectively [<xref rid="B152-ijms-17-01555" ref-type="bibr">152</xref>]. <xref ref-type="fig" rid="ijms-17-01555-f003">Figure 3</xref> represents the different pillars of a biomarker discovery pipeline.</p></sec><sec id="sec3dot3-ijms-17-01555"><title>3.3. Criteria for Omics-Based Biomarkers in Clinical Context</title><p>Three main aspects entail omics-based test development: analytical development, computational modeling of the predictor, and its clinical utility validation. Given the multi-dimensional and rich information generated by omics data, mathematical modeling is the key to building classifiers for effective medical decision-making. Because omics data are high-dimensional, machine learning and chemometric methods are needed to obtain insights from the data [<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>]. These methods may be divided into two main classes: unsupervised and supervised methods [<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. Unsupervised methods are exploratory and track patterns in the data; they include principal component analysis [<xref rid="B153-ijms-17-01555" ref-type="bibr">153</xref>], independent component analysis [<xref rid="B154-ijms-17-01555" ref-type="bibr">154</xref>], k-means clustering [<xref rid="B155-ijms-17-01555" ref-type="bibr">155</xref>], hierarchical cluster analysis [<xref rid="B156-ijms-17-01555" ref-type="bibr">156</xref>], and self-organizing maps [<xref rid="B157-ijms-17-01555" ref-type="bibr">157</xref>]. Supervised methods are mainly predictive and explanatory. They model the dataset so that the class label of separate validation set samples can be predicted based on a series of mathematical models derived from the original data, namely the training set. Different supervised methods such as PLS discriminant analysis (PLS-DA) [<xref rid="B158-ijms-17-01555" ref-type="bibr">158</xref>] and orthogonal PLS-DA (OPLS-DA) [<xref rid="B159-ijms-17-01555" ref-type="bibr">159</xref>], as well as support vector machines [<xref rid="B160-ijms-17-01555" ref-type="bibr">160</xref>], could be applied. For more details, the reader may refer to a recent review [<xref rid="B76-ijms-17-01555" ref-type="bibr">76</xref>]. <xref ref-type="fig" rid="ijms-17-01555-f004">Figure 4</xref> presents a schematic view of the two main computational modeling strategies using machine learning techniques for omics-based biomarker implementation.</p><p>The high-dimensionality characteristic of omics data requires new approaches for omics-based biomarkers development. McShane et al. described the main issues to take into account during omics-based biomarker development, including samples, analytical development of assays, computational model development, clinical utility assessment, and ethical and regulatory issues. The authors suggested criteria that should be assessed for effective biomarker validation [<xref rid="B161-ijms-17-01555" ref-type="bibr">161</xref>]. All these steps raise specific challenges regarding validation practices and determine the use of these omics-based tests [<xref rid="B100-ijms-17-01555" ref-type="bibr">100</xref>]. A stepwise approach of using machine learning methods for clinical phenotypes prediction and omics-based predictor development spanning from data collection to large-scale clinical validation are presented in <xref ref-type="fig" rid="ijms-17-01555-f005">Figure 5</xref>.</p></sec><sec id="sec3dot4-ijms-17-01555"><title>3.4. Omics Integration and the Curse of Dimensionality</title><p>Biomedical data are becoming quantitatively (number of samples) and qualitatively (data heterogeneity) complex. The number of samples is driven by the ever-growing high throughput of data acquisition technologies and their digitization, whereas heterogeneity entails biological features (biomolecules, diseases) and related metadata (sampling metadata and clinical data). Furthermore, data could be acquired through different platforms, thus adding bias, complexity, and noise. For these issues, machine learning methods are suitable for data modeling and integration [<xref rid="B162-ijms-17-01555" ref-type="bibr">162</xref>]. Data integrative methods can holistically analyze multiple data types to provide systems-level biological insights [<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>]. Dimensionality reduction techniques have been widely used to handle the biomedical big data deluge, but on a large scale they are computationally intensive. To handle these issues, topological data analysis (TDA) methods may help. TDA methods have emerged recently, but the concept goes back to Leonhard Euler and his work with algebraic topology in the 16th century. TDA methods acquire insight from data by analyzing their shapes (patterns) with geometric dimensional conversions [<xref rid="B163-ijms-17-01555" ref-type="bibr">163</xref>,<xref rid="B164-ijms-17-01555" ref-type="bibr">164</xref>,<xref rid="B165-ijms-17-01555" ref-type="bibr">165</xref>]. These methods have shown good performance in finding hidden patterns when other standard methods fail [<xref rid="B95-ijms-17-01555" ref-type="bibr">95</xref>,<xref rid="B163-ijms-17-01555" ref-type="bibr">163</xref>,<xref rid="B166-ijms-17-01555" ref-type="bibr">166</xref>]. Parsimony phylogenetic analysis is another promising method to handle the omics data deluge [<xref rid="B167-ijms-17-01555" ref-type="bibr">167</xref>]. Disease subtype classification for patient stratification is both data-dependent and method-dependent. Thus, it is urgent to have a representative and consistent reference dataset that can be used for the comparison and evaluation of methods.</p></sec></sec><sec id="sec4-ijms-17-01555"><title>4. Perspectives and Challenges in Translational and Clinical Contexts</title><sec id="sec4dot1-ijms-17-01555"><title>4.1. Data Integrity, Standardization, and Sharing</title><p>Data quality, integrity, and security are the keys to retrieving and maintaining the flow of data and are essential for achieving the promise of &#x0201c;precise&#x0201d; medicine. Data sharing can allow a study to proceed despite the low number of participants, which is often the case in IEM studies. However, the key drivers of data sharing are data and meta-data standards. These are essential for successful data integration and exchange. The lack of such standards or their inconsistent use, especially in omics, are the main drawbacks [<xref rid="B102-ijms-17-01555" ref-type="bibr">102</xref>]. Furthermore, in addition to global harmonization, new adapted regulatory approaches for these new omics strategies are urgently needed [<xref rid="B168-ijms-17-01555" ref-type="bibr">168</xref>,<xref rid="B169-ijms-17-01555" ref-type="bibr">169</xref>].</p><p>Large amounts of acquired data raise complex challenges for healthcare stakeholders, including patients. These challenges include the following: (i) sample collection, handling, storage, and transport; (ii) data analyses using multi-omics integration techniques; and (iii) collecting electronic medical record data. The integration of medical record data with biological data and their analysis are other issues. Finally, data sharing within the scientific community raises controversial legal, ethical, and privacy concerns as well [<xref rid="B170-ijms-17-01555" ref-type="bibr">170</xref>,<xref rid="B171-ijms-17-01555" ref-type="bibr">171</xref>].</p></sec><sec id="sec4dot2-ijms-17-01555"><title>4.2. Turning Data into Knowledge</title><p>Although molecular biomarkers have helped to unveil the underlying pathophysiological mechanisms of disease, only a few of the currently known biomarkers are clinically actionable [<xref rid="B172-ijms-17-01555" ref-type="bibr">172</xref>]. When introducing a biomarker to the clinic, it is important to consider its functional characterization through pathways and network analysis, along with its implementation feasibility in terms of public health. Despite the progress in patient phenotyping and stratification, new methods are needed to address the PM era challenges, including analyses of large data [<xref rid="B173-ijms-17-01555" ref-type="bibr">173</xref>], integration of multi-type data [<xref rid="B174-ijms-17-01555" ref-type="bibr">174</xref>], and simulation of disease behaviors across multi-scale modeling in space and time [<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>,<xref rid="B175-ijms-17-01555" ref-type="bibr">175</xref>,<xref rid="B176-ijms-17-01555" ref-type="bibr">176</xref>,<xref rid="B177-ijms-17-01555" ref-type="bibr">177</xref>].</p></sec><sec id="sec4dot3-ijms-17-01555"><title>4.3. Clinical Research Enterprise and Embracing Multi-Disciplinary Sciences</title><p>The new omics revolution will play a central role in the post-genomics era of healthcare. To achieve this promise, it is necessary to combine expertise from multiple disciplines, including clinicians, medical laboratory professionals, data scientists, computational biologists, biostatisticians, and lawyers. This observation increases the necessity for new PM teams with new skill sets to develop overlapping expertise for more effective medical interactions across all healthcare partners. Hence, the skill sets of medical professionals need to be diverse; clinical, biological, and computational knowledge to achieve the promises of PM. Training the new generation of the medical workforce to manage and interpret omics data is one solution, and inception of such thinking has already started [<xref rid="B178-ijms-17-01555" ref-type="bibr">178</xref>,<xref rid="B179-ijms-17-01555" ref-type="bibr">179</xref>,<xref rid="B180-ijms-17-01555" ref-type="bibr">180</xref>]. Clinical bioinformatics provides a bridge between omics sciences and clinical practices [<xref rid="B181-ijms-17-01555" ref-type="bibr">181</xref>]. We are facing an urgent need to transform all aspects of the healthcare system.</p></sec><sec id="sec4dot4-ijms-17-01555"><title>4.4. Informatics and New Pathways to Clinical Actionability</title><p>Informatics research and innovation are key drivers of the science underlying PM [<xref rid="B181-ijms-17-01555" ref-type="bibr">181</xref>]. Actionable biomarkers that aid in clinical decision-making will be envisioned by new frameworks to navigate multi-level evidence regarding whether and how a detected molecular abnormality might be a clinically relevant biomarker [<xref rid="B11-ijms-17-01555" ref-type="bibr">11</xref>]. Thanks to databases, accurate annotations with contextual and actionable clinical information will enable the emergence of decision support systems to provide intuitive and patient-specific actionable reports [<xref rid="B87-ijms-17-01555" ref-type="bibr">87</xref>,<xref rid="B182-ijms-17-01555" ref-type="bibr">182</xref>,<xref rid="B183-ijms-17-01555" ref-type="bibr">183</xref>]. Urgent areas to be addressed by clinical bioinformatics research may include biomarker discovery, computational phenotyping, and frameworks for evaluating clinical actionability and utility [<xref rid="B181-ijms-17-01555" ref-type="bibr">181</xref>,<xref rid="B184-ijms-17-01555" ref-type="bibr">184</xref>,<xref rid="B185-ijms-17-01555" ref-type="bibr">185</xref>]. Furthermore, standardization and harmonization-related barriers might trap interoperability and integration by making data aggregation a challenging task [<xref rid="B87-ijms-17-01555" ref-type="bibr">87</xref>].</p></sec></sec><sec id="sec5-ijms-17-01555"><title>5. Paradigm Shift in IEM Investigations</title><p>Because IEM are linked to a genetic defect, their current characterization addresses the mutated gene and its products. However, genotype&#x02013;phenotype correlation is lacking in several IEM, which leads to consideration of the influence of genetic or environmental modifying factors and the impact of an altered pathway on metabolic flux as a whole. These diseases are related to the disruption of specific interactions in a highly organized metabolic network [<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>,<xref rid="B186-ijms-17-01555" ref-type="bibr">186</xref>]. Thus, the impact of a given disruption is not easily predictable [<xref rid="B6-ijms-17-01555" ref-type="bibr">6</xref>,<xref rid="B187-ijms-17-01555" ref-type="bibr">187</xref>]. Therefore, a functional overview integrating both space and time dimensions is needed to assess the actors of the altered pathway and the potential interactions of each actor [<xref rid="B4-ijms-17-01555" ref-type="bibr">4</xref>]. Systemic approaches may address IEM complexity and allow their diagnosis [<xref rid="B10-ijms-17-01555" ref-type="bibr">10</xref>,<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>]. The effectiveness of such approaches has been recently illustrated by van Karnebeek et al. These authors observed a disruption of the <italic>N</italic>-acetylneuraminic acid pathway in patients with severe developmental delay and skeletal dysplasia by using both genomics and metabolomics approaches. As a result, variations in the <italic>NANS</italic> gene encoding the synthase for <italic>N</italic>-acetylneuraminic acid have been identified [<xref rid="B10-ijms-17-01555" ref-type="bibr">10</xref>].</p><p>Omics-generated data and clinical data integration allow a paradigm shift in IEM handling. An innovative global approach that involves extracting the useful and actionable information may change screening and diagnosis practices. Therefore, a disruptive move from sequential and hypothesis-driven approaches to a global and hypothesis-generating approach is mandatory to embrace the PM era. The core idea of the paradigm shift in the IEM diagnosis workflow is presented in <xref ref-type="fig" rid="ijms-17-01555-f006">Figure 6</xref>.</p></sec><sec id="sec6-ijms-17-01555"><title>6. Conclusions</title><p>Current medical practice is being undermined and PM is profoundly reshaping the future of medicine through recent technological advances. Omics technologies are enabling the simultaneous measurement of a huge number of biochemical entities, including genes, genes expressions, proteins, and metabolites. After decades of reductionism, holistic approaches have begun to address inborn errors of metabolism in a systemic fashion [<xref rid="B9-ijms-17-01555" ref-type="bibr">9</xref>,<xref rid="B64-ijms-17-01555" ref-type="bibr">64</xref>,<xref rid="B91-ijms-17-01555" ref-type="bibr">91</xref>]. Despite some existing drawbacks, genomics and metabolomics seem to be taking the lead in the race to get into clinical practice. However, challenges such as data quality/integrity, reproducibility, and study sample sizes have to be addressed. The small number of multi-omics datasets in the field of IEM and the lack of standardized and harmonized protocols affect the wide dissemination of these approaches. To overcome these drawbacks, attention should be given to validation strategies at all stages. Moreover, the development of new analytical and machine learning methods will facilitate analysis of multi-tissue and multi-organ data, thus enabling a real investigation of systemic effects [<xref rid="B95-ijms-17-01555" ref-type="bibr">95</xref>,<xref rid="B141-ijms-17-01555" ref-type="bibr">141</xref>,<xref rid="B163-ijms-17-01555" ref-type="bibr">163</xref>]. Extended and effective resources for biobanking are also essential to ensure consistency. Addressing these challenges will improve healthcare management of IEM by moving from a reactive, targeted, and reductionist approach to a more proactive, global, and integrative one.</p><p>Upgrading laboratory informatics infrastructures and a new medical workforce trained in biomedical big data management are necessary for the successful integration of omics-based strategies. However, the potential of these strategies in the investigation of IEM has yet to be unveiled to all IEM stakeholders worldwide. Laboratory workflows with high-quality data acquisition, mining, and visualization are fundamental for fully embracing the four Ps (predictive, personalized, preventive, and participatory) of PM [<xref rid="B188-ijms-17-01555" ref-type="bibr">188</xref>] and effectively translating the underlying biological knowledge into clinically actionable tools.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by Normandy University, the Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (INSERM), the Conseil R&#x000e9;gional de Normandie, Labex SynOrg (ANR-11-LABX-0029), and the European Regional Development Fund (ERDF 31708).</p></ack><notes><title>Author Contributions</title><p>Abdellah Tebani performed the literature review and wrote the manuscript, including tables and figures. Carlos Afonso critically revised and edited the manuscript. St&#x000e9;phane Marret critically revised and edited the manuscript. Soumeya Bekri conceived the topic under review and critically revised and edited the manuscript. All authors approved the final manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATAC-seq</td><td align="left" valign="middle" rowspan="1" colspan="1">Assay for transposase-accessible chromatin next-generation sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BAM</td><td align="left" valign="middle" rowspan="1" colspan="1">Binary alignment map</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ChIP-seq</td><td align="left" valign="middle" rowspan="1" colspan="1">Chromatin immunoprecipitation next-generation sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CT</td><td align="left" valign="middle" rowspan="1" colspan="1">Computerized tomography</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Deoxyribonucleic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DNase-seq</td><td align="left" valign="middle" rowspan="1" colspan="1">DNase I digestion of chromatin combined with next-generation sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTS</td><td align="left" valign="middle" rowspan="1" colspan="1">High-throughput sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICA</td><td align="left" valign="middle" rowspan="1" colspan="1">Independent component analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IEM</td><td align="left" valign="middle" rowspan="1" colspan="1">Inborn errors of metabolism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iPF</td><td align="left" valign="middle" rowspan="1" colspan="1">Integrative phenotyping framework</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">miRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ML</td><td align="left" valign="middle" rowspan="1" colspan="1">Machine learning</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRI</td><td align="left" valign="middle" rowspan="1" colspan="1">Magnetic resonance imaging</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MS</td><td align="left" valign="middle" rowspan="1" colspan="1">Mass spectrometry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MS/MS</td><td align="left" valign="middle" rowspan="1" colspan="1">Tandem mass spectrometry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ncRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-coding RNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGS</td><td align="left" valign="middle" rowspan="1" colspan="1">Next-generation sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OPLSDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Orthogonal partial least squares discriminant analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCA</td><td align="left" valign="middle" rowspan="1" colspan="1">Principal component analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLSDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Partial least squares discriminant analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PM</td><td align="left" valign="middle" rowspan="1" colspan="1">Precision medicine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QC</td><td align="left" valign="middle" rowspan="1" colspan="1">Quality control</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ribonucleic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ribosome RNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAM</td><td align="left" valign="middle" rowspan="1" colspan="1">Sequence alignment map</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNP</td><td align="left" valign="middle" rowspan="1" colspan="1">Single-nucleotide polymorphisms</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SOM</td><td align="left" valign="middle" rowspan="1" colspan="1">Self-organizing maps</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SOP</td><td align="left" valign="middle" rowspan="1" colspan="1">Standard operating procedure</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SVM</td><td align="left" valign="middle" rowspan="1" colspan="1">Support vector machines</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Topological data analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">tRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Transfer RNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCF</td><td align="left" valign="middle" rowspan="1" colspan="1">Variant call format</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WES</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole-exome sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WGS</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole-genome sequencing</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-17-01555"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>F.S.</given-names></name><name><surname>Varmus</surname><given-names>H.</given-names></name></person-group>
<article-title>A new initiative on precision medicine</article-title>
<source>N. Engl. J. Med.</source>
<year>2015</year>
<volume>372</volume>
<fpage>793</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMp1500523</pub-id>
<?supplied-pmid 25635347?><pub-id pub-id-type="pmid">25635347</pub-id></element-citation></ref><ref id="B2-ijms-17-01555"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahn</surname><given-names>A.C.</given-names></name><name><surname>Tewari</surname><given-names>M.</given-names></name><name><surname>Poon</surname><given-names>C.S.</given-names></name><name><surname>Phillips</surname><given-names>R.S.</given-names></name></person-group>
<article-title>The limits of reductionism in medicine: Could systems biology offer an alternative?</article-title>
<source>PLoS Med.</source>
<year>2006</year>
<volume>3</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.0030208</pub-id>
<?supplied-pmid 16681415?><pub-id pub-id-type="pmid">16681415</pub-id></element-citation></ref><ref id="B3-ijms-17-01555"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Regenmortel</surname><given-names>M.H.</given-names></name></person-group>
<article-title>Reductionism and complexity in molecular biology: Scientists now have the tools to unravel biological and overcome the limitations of reductionism</article-title>
<source>EMBO Rep.</source>
<year>2004</year>
<volume>5</volume>
<fpage>1016</fpage>
<lpage>1020</lpage>
<pub-id pub-id-type="doi">10.1038/sj.embor.7400284</pub-id>
<?supplied-pmid 15520799?><pub-id pub-id-type="pmid">15520799</pub-id></element-citation></ref><ref id="B4-ijms-17-01555"><label>4.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Aon</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Complex systems biology of networks: The riddle and the challenge</article-title>
<source>Systems Biology of Metabolic and Signaling Networks</source>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Heidelberg, Germany</publisher-loc>
<year>2014</year>
<fpage>19</fpage>
<lpage>35</lpage>
</element-citation></ref><ref id="B5-ijms-17-01555"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kitano</surname><given-names>H.</given-names></name></person-group>
<article-title>Systems biology: A brief overview</article-title>
<source>Science</source>
<year>2002</year>
<volume>295</volume>
<fpage>1662</fpage>
<lpage>1664</lpage>
<pub-id pub-id-type="doi">10.1126/science.1069492</pub-id>
<?supplied-pmid 11872829?><pub-id pub-id-type="pmid">11872829</pub-id></element-citation></ref><ref id="B6-ijms-17-01555"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lanpher</surname><given-names>B.</given-names></name><name><surname>Brunetti-Pierri</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name></person-group>
<article-title>Inborn errors of metabolism: The flux from mendelian to complex diseases</article-title>
<source>Nat. Rev. Genet.</source>
<year>2006</year>
<volume>7</volume>
<fpage>449</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1038/nrg1880</pub-id>
<?supplied-pmid 16708072?><pub-id pub-id-type="pmid">16708072</pub-id></element-citation></ref><ref id="B7-ijms-17-01555"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watson</surname><given-names>J.D.</given-names></name><name><surname>Crick</surname><given-names>F.H.</given-names></name></person-group>
<article-title>The structure of DNA</article-title>
<source>Cold Spring Harb. Symp. Quant. Biol.</source>
<year>1953</year>
<volume>18</volume>
<fpage>123</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1101/SQB.1953.018.01.020</pub-id>
<?supplied-pmid 13168976?><pub-id pub-id-type="pmid">13168976</pub-id></element-citation></ref><ref id="B8-ijms-17-01555"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>S.</given-names></name><name><surname>McPherson</surname><given-names>J.D.</given-names></name><name><surname>McCombie</surname><given-names>W.R.</given-names></name></person-group>
<article-title>Coming of age: Ten years of next-generation sequencing technologies</article-title>
<source>Nat. Rev. Genet.</source>
<year>2016</year>
<volume>17</volume>
<fpage>333</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1038/nrg.2016.49</pub-id>
<?supplied-pmid 27184599?><pub-id pub-id-type="pmid">27184599</pub-id></element-citation></ref><ref id="B9-ijms-17-01555"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Muzny</surname><given-names>D.M.</given-names></name><name><surname>Reid</surname><given-names>J.G.</given-names></name><name><surname>Bainbridge</surname><given-names>M.N.</given-names></name><name><surname>Willis</surname><given-names>A.</given-names></name><name><surname>Ward</surname><given-names>P.A.</given-names></name><name><surname>Braxton</surname><given-names>A.</given-names></name><name><surname>Beuten</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>F.</given-names></name><name><surname>Niu</surname><given-names>Z.</given-names></name><etal/></person-group>
<article-title>Clinical whole-exome sequencing for the diagnosis of mendelian disorders</article-title>
<source>N. Engl. J. Med.</source>
<year>2013</year>
<volume>369</volume>
<fpage>1502</fpage>
<lpage>1511</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1306555</pub-id>
<?supplied-pmid 24088041?><pub-id pub-id-type="pmid">24088041</pub-id></element-citation></ref><ref id="B10-ijms-17-01555"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Karnebeek</surname><given-names>C.D.</given-names></name><name><surname>Bonafe</surname><given-names>L.</given-names></name><name><surname>Wen</surname><given-names>X.Y.</given-names></name><name><surname>Tarailo-Graovac</surname><given-names>M.</given-names></name><name><surname>Balzano</surname><given-names>S.</given-names></name><name><surname>Royer-Bertrand</surname><given-names>B.</given-names></name><name><surname>Ashikov</surname><given-names>A.</given-names></name><name><surname>Garavelli</surname><given-names>L.</given-names></name><name><surname>Mammi</surname><given-names>I.</given-names></name><name><surname>Turolla</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>Nans-mediated synthesis of sialic acid is required for brain and skeletal development</article-title>
<source>Nat. Genet.</source>
<year>2016</year>
<volume>48</volume>
<fpage>777</fpage>
<lpage>784</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3578</pub-id>
<?supplied-pmid 27213289?><pub-id pub-id-type="pmid">27213289</pub-id></element-citation></ref><ref id="B11-ijms-17-01555"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarailo-Graovac</surname><given-names>M.</given-names></name><name><surname>Shyr</surname><given-names>C.</given-names></name><name><surname>Ross</surname><given-names>C.J.</given-names></name><name><surname>Horvath</surname><given-names>G.A.</given-names></name><name><surname>Salvarinova</surname><given-names>R.</given-names></name><name><surname>Ye</surname><given-names>X.C.</given-names></name><name><surname>Zhang</surname><given-names>L.H.</given-names></name><name><surname>Bhavsar</surname><given-names>A.P.</given-names></name><name><surname>Lee</surname><given-names>J.J.</given-names></name><name><surname>Drogemoller</surname><given-names>B.I.</given-names></name><etal/></person-group>
<article-title>Exome sequencing and the management of neurometabolic disorders</article-title>
<source>N. Engl. J. Med.</source>
<year>2016</year>
<volume>374</volume>
<fpage>2246</fpage>
<lpage>2255</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1515792</pub-id>
<?supplied-pmid 27276562?><pub-id pub-id-type="pmid">27276562</pub-id></element-citation></ref><ref id="B12-ijms-17-01555"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Worthey</surname><given-names>E.A.</given-names></name><name><surname>Mayer</surname><given-names>A.N.</given-names></name><name><surname>Syverson</surname><given-names>G.D.</given-names></name><name><surname>Helbling</surname><given-names>D.</given-names></name><name><surname>Bonacci</surname><given-names>B.B.</given-names></name><name><surname>Decker</surname><given-names>B.</given-names></name><name><surname>Serpe</surname><given-names>J.M.</given-names></name><name><surname>Dasu</surname><given-names>T.</given-names></name><name><surname>Tschannen</surname><given-names>M.R.</given-names></name><name><surname>Veith</surname><given-names>R.L.</given-names></name><etal/></person-group>
<article-title>Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease</article-title>
<source>Genet. Med.</source>
<year>2011</year>
<volume>13</volume>
<fpage>255</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1097/GIM.0b013e3182088158</pub-id>
<?supplied-pmid 21173700?><pub-id pub-id-type="pmid">21173700</pub-id></element-citation></ref><ref id="B13-ijms-17-01555"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benson</surname><given-names>M.</given-names></name></person-group>
<article-title>Clinical implications of omics and systems medicine: Focus on predictive and individualized treatment</article-title>
<source>J. Intern. Med.</source>
<year>2016</year>
<volume>279</volume>
<fpage>229</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1111/joim.12412</pub-id>
<?supplied-pmid 26891944?><pub-id pub-id-type="pmid">26891944</pub-id></element-citation></ref><ref id="B14-ijms-17-01555"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yohe</surname><given-names>S.</given-names></name><name><surname>Hauge</surname><given-names>A.</given-names></name><name><surname>Bunjer</surname><given-names>K.</given-names></name><name><surname>Kemmer</surname><given-names>T.</given-names></name><name><surname>Bower</surname><given-names>M.</given-names></name><name><surname>Schomaker</surname><given-names>M.</given-names></name><name><surname>Onsongo</surname><given-names>G.</given-names></name><name><surname>Wilson</surname><given-names>J.</given-names></name><name><surname>Erdmann</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group>
<article-title>Clinical validation of targeted next-generation sequencing for inherited disorders</article-title>
<source>Arch. Pathol. Lab. Med.</source>
<year>2015</year>
<volume>139</volume>
<fpage>204</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.5858/arpa.2013-0625-OA</pub-id>
<?supplied-pmid 25611102?><pub-id pub-id-type="pmid">25611102</pub-id></element-citation></ref><ref id="B15-ijms-17-01555"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yubero</surname><given-names>D.</given-names></name><name><surname>Brandi</surname><given-names>N.</given-names></name><name><surname>Ormazabal</surname><given-names>A.</given-names></name><name><surname>Garcia-Cazorla</surname><given-names>A.</given-names></name><name><surname>Perez-Duenas</surname><given-names>B.</given-names></name><name><surname>Campistol</surname><given-names>J.</given-names></name><name><surname>Ribes</surname><given-names>A.</given-names></name><name><surname>Palau</surname><given-names>F.</given-names></name><name><surname>Artuch</surname><given-names>R.</given-names></name><name><surname>Armstrong</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Targeted next generation sequencing in patients with inborn errors of metabolism</article-title>
<source>PLoS ONE</source>
<year>2016</year>
<volume>11</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0156359</pub-id>
<?supplied-pmid 27243974?><pub-id pub-id-type="pmid">27243974</pub-id></element-citation></ref><ref id="B16-ijms-17-01555"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cirulli</surname><given-names>E.T.</given-names></name><name><surname>Goldstein</surname><given-names>D.B.</given-names></name></person-group>
<article-title>Uncovering the roles of rare variants in common disease through whole-genome sequencing</article-title>
<source>Nat. Rev. Genet.</source>
<year>2010</year>
<volume>11</volume>
<fpage>415</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2779</pub-id>
<?supplied-pmid 20479773?><pub-id pub-id-type="pmid">20479773</pub-id></element-citation></ref><ref id="B17-ijms-17-01555"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stranneheim</surname><given-names>H.</given-names></name><name><surname>Wedell</surname><given-names>A.</given-names></name></person-group>
<article-title>Exome and genome sequencing: A revolution for the discovery and diagnosis of monogenic disorders</article-title>
<source>J. Intern. Med.</source>
<year>2016</year>
<volume>279</volume>
<fpage>3</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1111/joim.12399</pub-id>
<?supplied-pmid 26250718?><pub-id pub-id-type="pmid">26250718</pub-id></element-citation></ref><ref id="B18-ijms-17-01555"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meienberg</surname><given-names>J.</given-names></name><name><surname>Zerjavic</surname><given-names>K.</given-names></name><name><surname>Keller</surname><given-names>I.</given-names></name><name><surname>Okoniewski</surname><given-names>M.</given-names></name><name><surname>Patrignani</surname><given-names>A.</given-names></name><name><surname>Ludin</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Steinmann</surname><given-names>B.</given-names></name><name><surname>Carrel</surname><given-names>T.</given-names></name><name><surname>Rothlisberger</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>New insights into the performance of human whole-exome capture platforms</article-title>
<source>Nucleic Acids Res.</source>
<year>2015</year>
<volume>43</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1093/nar/gkv216</pub-id>
<?supplied-pmid 25820422?><pub-id pub-id-type="pmid">25820422</pub-id></element-citation></ref><ref id="B19-ijms-17-01555"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>B.A.</given-names></name><name><surname>McCue</surname><given-names>K.</given-names></name><name><surname>Schaeffer</surname><given-names>L.</given-names></name><name><surname>Wold</surname><given-names>B.</given-names></name></person-group>
<article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title>
<source>Nat. Methods</source>
<year>2008</year>
<volume>5</volume>
<fpage>621</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id>
<?supplied-pmid 18516045?><pub-id pub-id-type="pmid">18516045</pub-id></element-citation></ref><ref id="B20-ijms-17-01555"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mensaert</surname><given-names>K.</given-names></name><name><surname>Denil</surname><given-names>S.</given-names></name><name><surname>Trooskens</surname><given-names>G.</given-names></name><name><surname>van Criekinge</surname><given-names>W.</given-names></name><name><surname>Thas</surname><given-names>O.</given-names></name><name><surname>de Meyer</surname><given-names>T.</given-names></name></person-group>
<article-title>Next-generation technologies and data analytical approaches for epigenomics</article-title>
<source>Environ. Mol. Mutagen.</source>
<year>2014</year>
<volume>55</volume>
<fpage>155</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1002/em.21841</pub-id>
<?supplied-pmid 24327356?><pub-id pub-id-type="pmid">24327356</pub-id></element-citation></ref><ref id="B21-ijms-17-01555"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanger</surname><given-names>F.</given-names></name><name><surname>Nicklen</surname><given-names>S.</given-names></name><name><surname>Coulson</surname><given-names>A.R.</given-names></name></person-group>
<article-title>DNA sequencing with chain-terminating inhibitors</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1977</year>
<volume>74</volume>
<fpage>5463</fpage>
<lpage>5467</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.74.12.5463</pub-id>
<?supplied-pmid 271968?><pub-id pub-id-type="pmid">271968</pub-id></element-citation></ref><ref id="B22-ijms-17-01555"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marsh</surname><given-names>M.</given-names></name><name><surname>Tu</surname><given-names>O.</given-names></name><name><surname>Dolnik</surname><given-names>V.</given-names></name><name><surname>Roach</surname><given-names>D.</given-names></name><name><surname>Solomon</surname><given-names>N.</given-names></name><name><surname>Bechtol</surname><given-names>K.</given-names></name><name><surname>Smietana</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Cartwright</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>High-throughput DNA sequencing on a capillary array electrophoresis system</article-title>
<source>J. Capill. Electrophor.</source>
<year>1997</year>
<volume>4</volume>
<fpage>83</fpage>
<lpage>89</lpage>
</element-citation></ref><ref id="B23-ijms-17-01555"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McBride</surname><given-names>L.J.</given-names></name><name><surname>Koepf</surname><given-names>S.M.</given-names></name><name><surname>Gibbs</surname><given-names>R.A.</given-names></name><name><surname>Salser</surname><given-names>W.</given-names></name><name><surname>Mayrand</surname><given-names>P.E.</given-names></name><name><surname>Hunkapiller</surname><given-names>M.W.</given-names></name><name><surname>Kronick</surname><given-names>M.N.</given-names></name></person-group>
<article-title>Automated DNA sequencing methods involving polymerase chain reaction</article-title>
<source>Clin. Chem.</source>
<year>1989</year>
<volume>35</volume>
<fpage>2196</fpage>
<lpage>2201</lpage>
<?supplied-pmid 2582616?><pub-id pub-id-type="pmid">2582616</pub-id></element-citation></ref><ref id="B24-ijms-17-01555"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prober</surname><given-names>J.M.</given-names></name><name><surname>Trainor</surname><given-names>G.L.</given-names></name><name><surname>Dam</surname><given-names>R.J.</given-names></name><name><surname>Hobbs</surname><given-names>F.W.</given-names></name><name><surname>Robertson</surname><given-names>C.W.</given-names></name><name><surname>Zagursky</surname><given-names>R.J.</given-names></name><name><surname>Cocuzza</surname><given-names>A.J.</given-names></name><name><surname>Jensen</surname><given-names>M.A.</given-names></name><name><surname>Baumeister</surname><given-names>K.</given-names></name></person-group>
<article-title>A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides</article-title>
<source>Science</source>
<year>1987</year>
<volume>238</volume>
<fpage>336</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1126/science.2443975</pub-id>
<?supplied-pmid 2443975?><pub-id pub-id-type="pmid">2443975</pub-id></element-citation></ref><ref id="B25-ijms-17-01555"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venter</surname><given-names>J.C.</given-names></name><name><surname>Adams</surname><given-names>M.D.</given-names></name><name><surname>Myers</surname><given-names>E.W.</given-names></name><name><surname>Li</surname><given-names>P.W.</given-names></name><name><surname>Mural</surname><given-names>R.J.</given-names></name><name><surname>Sutton</surname><given-names>G.G.</given-names></name><name><surname>Smith</surname><given-names>H.O.</given-names></name><name><surname>Yandell</surname><given-names>M.</given-names></name><name><surname>Evans</surname><given-names>C.A.</given-names></name><name><surname>Holt</surname><given-names>R.A.</given-names></name><etal/></person-group>
<article-title>The sequence of the human genome</article-title>
<source>Science</source>
<year>2001</year>
<volume>291</volume>
<fpage>1304</fpage>
<lpage>1351</lpage>
<pub-id pub-id-type="doi">10.1126/science.1058040</pub-id>
<?supplied-pmid 11181995?><pub-id pub-id-type="pmid">11181995</pub-id></element-citation></ref><ref id="B26-ijms-17-01555"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Linton</surname><given-names>L.M.</given-names></name><name><surname>Birren</surname><given-names>B.</given-names></name><name><surname>Nusbaum</surname><given-names>C.</given-names></name><name><surname>Zody</surname><given-names>M.C.</given-names></name><name><surname>Baldwin</surname><given-names>J.</given-names></name><name><surname>Devon</surname><given-names>K.</given-names></name><name><surname>Dewar</surname><given-names>K.</given-names></name><name><surname>Doyle</surname><given-names>M.</given-names></name><name><surname>FitzHugh</surname><given-names>W.</given-names></name><etal/></person-group>
<article-title>Initial sequencing and analysis of the human genome</article-title>
<source>Nature</source>
<year>2001</year>
<volume>409</volume>
<fpage>860</fpage>
<lpage>921</lpage>
<pub-id pub-id-type="doi">10.1038/35057062</pub-id>
<?supplied-pmid 11237011?><pub-id pub-id-type="pmid">11237011</pub-id></element-citation></ref><ref id="B27-ijms-17-01555"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reuter</surname><given-names>J.A.</given-names></name><name><surname>Spacek</surname><given-names>D.V.</given-names></name><name><surname>Snyder</surname><given-names>M.P.</given-names></name></person-group>
<article-title>High-throughput sequencing technologies</article-title>
<source>Mol. Cell</source>
<year>2015</year>
<volume>58</volume>
<fpage>586</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2015.05.004</pub-id>
<?supplied-pmid 26000844?><pub-id pub-id-type="pmid">26000844</pub-id></element-citation></ref><ref id="B28-ijms-17-01555"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Head</surname><given-names>S.R.</given-names></name><name><surname>Komori</surname><given-names>H.K.</given-names></name><name><surname>LaMere</surname><given-names>S.A.</given-names></name><name><surname>Whisenant</surname><given-names>T.</given-names></name><name><surname>van Nieuwerburgh</surname><given-names>F.</given-names></name><name><surname>Salomon</surname><given-names>D.R.</given-names></name><name><surname>Ordoukhanian</surname><given-names>P.</given-names></name></person-group>
<article-title>Library construction for next-generation sequencing: Overviews and challenges</article-title>
<source>Biotechniques</source>
<year>2014</year>
<volume>56</volume>
<fpage>61</fpage>
<pub-id pub-id-type="doi">10.2144/000114133</pub-id>
<?supplied-pmid 24502796?><pub-id pub-id-type="pmid">24502796</pub-id></element-citation></ref><ref id="B29-ijms-17-01555"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mardis</surname><given-names>E.R.</given-names></name></person-group>
<article-title>Next-generation sequencing platforms</article-title>
<source>Annu. Rev. Anal. Chem.</source>
<year>2013</year>
<volume>6</volume>
<fpage>287</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-anchem-062012-092628</pub-id>
<?supplied-pmid 23560931?><pub-id pub-id-type="pmid">23560931</pub-id></element-citation></ref><ref id="B30-ijms-17-01555"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>E.C.</given-names></name><name><surname>Brett</surname><given-names>M.</given-names></name><name><surname>Lai</surname><given-names>A.H.</given-names></name><name><surname>Lee</surname><given-names>S.P.</given-names></name><name><surname>Tan</surname><given-names>E.S.</given-names></name><name><surname>Jamuar</surname><given-names>S.S.</given-names></name><name><surname>Ng</surname><given-names>I.S.</given-names></name><name><surname>Tan</surname><given-names>E.C.</given-names></name></person-group>
<article-title>Next-generation sequencing using a pre-designed gene panel for the molecular diagnosis of congenital disorders in pediatric patients</article-title>
<source>Hum. Genom.</source>
<year>2015</year>
<volume>9</volume>
<fpage>33</fpage>
<pub-id pub-id-type="doi">10.1186/s40246-015-0055-x</pub-id>
<?supplied-pmid 26666243?><pub-id pub-id-type="pmid">26666243</pub-id></element-citation></ref><ref id="B31-ijms-17-01555"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R.W.</given-names></name><name><surname>Pyle</surname><given-names>A.</given-names></name><name><surname>Griffin</surname><given-names>H.</given-names></name><name><surname>Blakely</surname><given-names>E.L.</given-names></name><name><surname>Duff</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Smertenko</surname><given-names>T.</given-names></name><name><surname>Alston</surname><given-names>C.L.</given-names></name><name><surname>Neeve</surname><given-names>V.C.</given-names></name><name><surname>Best</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies</article-title>
<source>JAMA</source>
<year>2014</year>
<volume>312</volume>
<fpage>68</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2014.7184</pub-id>
<?supplied-pmid 25058219?><pub-id pub-id-type="pmid">25058219</pub-id></element-citation></ref><ref id="B32-ijms-17-01555"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Howard</surname><given-names>H.C.</given-names></name><name><surname>Knoppers</surname><given-names>B.M.</given-names></name><name><surname>Cornel</surname><given-names>M.C.</given-names></name><name><surname>Wright Clayton</surname><given-names>E.</given-names></name><name><surname>Senecal</surname><given-names>K.</given-names></name><name><surname>Borry</surname><given-names>P.</given-names></name></person-group>
<article-title>Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes</article-title>
<source>Eur. J. Hum. Genet.</source>
<year>2015</year>
<volume>23</volume>
<fpage>1593</fpage>
<lpage>1600</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2014.289</pub-id>
<?supplied-pmid 25626707?><pub-id pub-id-type="pmid">25626707</pub-id></element-citation></ref><ref id="B33-ijms-17-01555"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashley</surname><given-names>E.A.</given-names></name></person-group>
<article-title>Towards precision medicine</article-title>
<source>Nat. Rev. Genet.</source>
<year>2016</year>
<volume>17</volume>
<fpage>507</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1038/nrg.2016.86</pub-id>
<?supplied-pmid 27528417?><pub-id pub-id-type="pmid">27528417</pub-id></element-citation></ref><ref id="B34-ijms-17-01555"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldfeder</surname><given-names>R.L.</given-names></name><name><surname>Ashley</surname><given-names>E.A.</given-names></name></person-group>
<article-title>A precision metric for clinical genome sequencing</article-title>
<source>bioRxiv</source>
<year>2016</year>
<fpage>051490</fpage>
<pub-id pub-id-type="doi">10.1101/051490</pub-id>
</element-citation></ref><ref id="B35-ijms-17-01555"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bird</surname><given-names>A.</given-names></name></person-group>
<article-title>Perceptions of epigenetics</article-title>
<source>Nature</source>
<year>2007</year>
<volume>447</volume>
<fpage>396</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1038/nature05913</pub-id>
<?supplied-pmid 17522671?><pub-id pub-id-type="pmid">17522671</pub-id></element-citation></ref><ref id="B36-ijms-17-01555"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name></person-group>
<article-title>Epigenetics: The language of the cell?</article-title>
<source>Epigenomics</source>
<year>2014</year>
<volume>6</volume>
<fpage>73</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.2217/epi.13.72</pub-id>
<?supplied-pmid 24579948?><pub-id pub-id-type="pmid">24579948</pub-id></element-citation></ref><ref id="B37-ijms-17-01555"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadakierska-Chudy</surname><given-names>A.</given-names></name><name><surname>Filip</surname><given-names>M.</given-names></name></person-group>
<article-title>A comprehensive view of the epigenetic landscape. Part II: Histone post-translational modification, nucleosome level, and chromatin regulation by ncRNAs</article-title>
<source>Neurotox. Res.</source>
<year>2015</year>
<volume>27</volume>
<fpage>172</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-014-9508-6</pub-id>
<?supplied-pmid 25516120?><pub-id pub-id-type="pmid">25516120</pub-id></element-citation></ref><ref id="B38-ijms-17-01555"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadakierska-Chudy</surname><given-names>A.</given-names></name><name><surname>Kostrzewa</surname><given-names>R.M.</given-names></name><name><surname>Filip</surname><given-names>M.</given-names></name></person-group>
<article-title>A comprehensive view of the epigenetic landscape part I: DNA methylation, passive and active DNA demethylation pathways and histone variants</article-title>
<source>Neurotox. Res.</source>
<year>2015</year>
<volume>27</volume>
<fpage>84</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-014-9497-5</pub-id>
<?supplied-pmid 25362550?><pub-id pub-id-type="pmid">25362550</pub-id></element-citation></ref><ref id="B39-ijms-17-01555"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kundaje</surname><given-names>A.</given-names></name><name><surname>Meuleman</surname><given-names>W.</given-names></name><name><surname>Ernst</surname><given-names>J.</given-names></name><name><surname>Bilenky</surname><given-names>M.</given-names></name><name><surname>Yen</surname><given-names>A.</given-names></name><name><surname>Heravi-Moussavi</surname><given-names>A.</given-names></name><name><surname>Kheradpour</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ziller</surname><given-names>M.J.</given-names></name><etal/></person-group>
<article-title>Integrative analysis of 111 reference human epigenomes</article-title>
<source>Nature</source>
<year>2015</year>
<volume>518</volume>
<fpage>317</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1038/nature14248</pub-id>
<?supplied-pmid 25693563?><pub-id pub-id-type="pmid">25693563</pub-id></element-citation></ref><ref id="B40-ijms-17-01555"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barski</surname><given-names>A.</given-names></name><name><surname>Cuddapah</surname><given-names>S.</given-names></name><name><surname>Cui</surname><given-names>K.</given-names></name><name><surname>Roh</surname><given-names>T.Y.</given-names></name><name><surname>Schones</surname><given-names>D.E.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Chepelev</surname><given-names>I.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name></person-group>
<article-title>High-resolution profiling of histone methylations in the human genome</article-title>
<source>Cell</source>
<year>2007</year>
<volume>129</volume>
<fpage>823</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.05.009</pub-id>
<?supplied-pmid 17512414?><pub-id pub-id-type="pmid">17512414</pub-id></element-citation></ref><ref id="B41-ijms-17-01555"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yaragatti</surname><given-names>M.</given-names></name><name><surname>Basilico</surname><given-names>C.</given-names></name><name><surname>Dailey</surname><given-names>L.</given-names></name></person-group>
<article-title>Identification of active transcriptional regulatory modules by the functional assay of DNA from nucleosome-free regions</article-title>
<source>Genome Res.</source>
<year>2008</year>
<volume>18</volume>
<fpage>930</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="doi">10.1101/gr.073460.107</pub-id>
<?supplied-pmid 18441229?><pub-id pub-id-type="pmid">18441229</pub-id></element-citation></ref><ref id="B42-ijms-17-01555"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lister</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>R.C.</given-names></name><name><surname>Tonti-Filippini</surname><given-names>J.</given-names></name><name><surname>Gregory</surname><given-names>B.D.</given-names></name><name><surname>Berry</surname><given-names>C.C.</given-names></name><name><surname>Millar</surname><given-names>A.H.</given-names></name><name><surname>Ecker</surname><given-names>J.R.</given-names></name></person-group>
<article-title>Highly integrated single-base resolution maps of the epigenome in arabidopsis</article-title>
<source>Cell</source>
<year>2008</year>
<volume>133</volume>
<fpage>523</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.03.029</pub-id>
<?supplied-pmid 18423832?><pub-id pub-id-type="pmid">18423832</pub-id></element-citation></ref><ref id="B43-ijms-17-01555"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buenrostro</surname><given-names>J.D.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Greenleaf</surname><given-names>W.J.</given-names></name></person-group>
<article-title>Atac-seq: A method for assaying chromatin accessibility genome-wide</article-title>
<source>Curr. Protoc. Mol. Biol.</source>
<year>2015</year>
<volume>109</volume>
<pub-id pub-id-type="doi">10.1002/0471142727.mb2129s109</pub-id>
</element-citation></ref><ref id="B44-ijms-17-01555"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meyer</surname><given-names>C.A.</given-names></name><name><surname>Liu</surname><given-names>X.S.</given-names></name></person-group>
<article-title>Identifying and mitigating bias in next-generation sequencing methods for chromatin biology</article-title>
<source>Nat. Rev. Genet.</source>
<year>2014</year>
<volume>15</volume>
<fpage>709</fpage>
<lpage>721</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3788</pub-id>
<?supplied-pmid 25223782?><pub-id pub-id-type="pmid">25223782</pub-id></element-citation></ref><ref id="B45-ijms-17-01555"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guay</surname><given-names>S.P.</given-names></name><name><surname>Voisin</surname><given-names>G.</given-names></name><name><surname>Brisson</surname><given-names>D.</given-names></name><name><surname>Munger</surname><given-names>J.</given-names></name><name><surname>Lamarche</surname><given-names>B.</given-names></name><name><surname>Gaudet</surname><given-names>D.</given-names></name><name><surname>Bouchard</surname><given-names>L.</given-names></name></person-group>
<article-title>Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration</article-title>
<source>Epigenomics</source>
<year>2012</year>
<volume>4</volume>
<fpage>623</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.2217/epi.12.62</pub-id>
<?supplied-pmid 23244308?><pub-id pub-id-type="pmid">23244308</pub-id></element-citation></ref><ref id="B46-ijms-17-01555"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Gerstein</surname><given-names>M.</given-names></name><name><surname>Snyder</surname><given-names>M.</given-names></name></person-group>
<article-title>RNA-seq: A revolutionary tool for transcriptomics</article-title>
<source>Nat. Rev. Genet.</source>
<year>2009</year>
<volume>10</volume>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2484</pub-id>
<?supplied-pmid 19015660?><pub-id pub-id-type="pmid">19015660</pub-id></element-citation></ref><ref id="B47-ijms-17-01555"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nogales-Gadea</surname><given-names>G.</given-names></name><name><surname>Consuegra-Garcia</surname><given-names>I.</given-names></name><name><surname>Rubio</surname><given-names>J.C.</given-names></name><name><surname>Arenas</surname><given-names>J.</given-names></name><name><surname>Cuadros</surname><given-names>M.</given-names></name><name><surname>Camara</surname><given-names>Y.</given-names></name><name><surname>Torres-Torronteras</surname><given-names>J.</given-names></name><name><surname>Fiuza-Luces</surname><given-names>C.</given-names></name><name><surname>Lucia</surname><given-names>A.</given-names></name><name><surname>Martin</surname><given-names>M.A.</given-names></name><etal/></person-group>
<article-title>A transcriptomic approach to search for novel phenotypic regulators in mcardle disease</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0031718</pub-id>
<?supplied-pmid 22347505?><pub-id pub-id-type="pmid">22347505</pub-id></element-citation></ref><ref id="B48-ijms-17-01555"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazzoccoli</surname><given-names>G.</given-names></name><name><surname>Tomanin</surname><given-names>R.</given-names></name><name><surname>Mazza</surname><given-names>T.</given-names></name><name><surname>D&#x02019;Avanzo</surname><given-names>F.</given-names></name><name><surname>Salvalaio</surname><given-names>M.</given-names></name><name><surname>Rigon</surname><given-names>L.</given-names></name><name><surname>Zanetti</surname><given-names>A.</given-names></name><name><surname>Pazienza</surname><given-names>V.</given-names></name><name><surname>Francavilla</surname><given-names>M.</given-names></name><name><surname>Giuliani</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>Circadian transcriptome analysis in human fibroblasts from hunter syndrome and impact of iduronate-2-sulfatase treatment</article-title>
<source>BMC Med. Genom.</source>
<year>2013</year>
<volume>6</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1186/1755-8794-6-37</pub-id>
<?supplied-pmid 24083598?><pub-id pub-id-type="pmid">24083598</pub-id></element-citation></ref><ref id="B49-ijms-17-01555"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tringham</surname><given-names>M.</given-names></name><name><surname>Kurko</surname><given-names>J.</given-names></name><name><surname>Tanner</surname><given-names>L.</given-names></name><name><surname>Tuikkala</surname><given-names>J.</given-names></name><name><surname>Nevalainen</surname><given-names>O.S.</given-names></name><name><surname>Niinikoski</surname><given-names>H.</given-names></name><name><surname>Nanto-Salonen</surname><given-names>K.</given-names></name><name><surname>Hietala</surname><given-names>M.</given-names></name><name><surname>Simell</surname><given-names>O.</given-names></name><name><surname>Mykkanen</surname><given-names>J.</given-names></name></person-group>
<article-title>Exploring the transcriptomic variation caused by the finnish founder mutation of lysinuric protein intolerance (LPI)</article-title>
<source>Mol. Genet. Metab.</source>
<year>2012</year>
<volume>105</volume>
<fpage>408</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2011.12.007</pub-id>
<?supplied-pmid 22221392?><pub-id pub-id-type="pmid">22221392</pub-id></element-citation></ref><ref id="B50-ijms-17-01555"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dauphinot</surname><given-names>L.</given-names></name><name><surname>Mockel</surname><given-names>L.</given-names></name><name><surname>Cahu</surname><given-names>J.</given-names></name><name><surname>Jinnah</surname><given-names>H.A.</given-names></name><name><surname>Ledroit</surname><given-names>M.</given-names></name><name><surname>Potier</surname><given-names>M.C.</given-names></name><name><surname>Ceballos-Picot</surname><given-names>I.</given-names></name></person-group>
<article-title>Transcriptomic approach to Lesch&#x02013;Nyhan disease</article-title>
<source>Nucleosides Nucleotides Nucleic Acids</source>
<year>2014</year>
<volume>33</volume>
<fpage>208</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1080/15257770.2014.880477</pub-id>
<?supplied-pmid 24940671?><pub-id pub-id-type="pmid">24940671</pub-id></element-citation></ref><ref id="B51-ijms-17-01555"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cluzeau</surname><given-names>C.V.</given-names></name><name><surname>Watkins-Chow</surname><given-names>D.E.</given-names></name><name><surname>Fu</surname><given-names>R.</given-names></name><name><surname>Borate</surname><given-names>B.</given-names></name><name><surname>Yanjanin</surname><given-names>N.</given-names></name><name><surname>Dail</surname><given-names>M.K.</given-names></name><name><surname>Davidson</surname><given-names>C.D.</given-names></name><name><surname>Walkley</surname><given-names>S.U.</given-names></name><name><surname>Ory</surname><given-names>D.S.</given-names></name><name><surname>Wassif</surname><given-names>C.A.</given-names></name><etal/></person-group>
<article-title>Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1</article-title>
<source>Hum. Mol. Genet.</source>
<year>2012</year>
<volume>21</volume>
<fpage>3632</fpage>
<lpage>3646</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds193</pub-id>
<?supplied-pmid 22619379?><pub-id pub-id-type="pmid">22619379</pub-id></element-citation></ref><ref id="B52-ijms-17-01555"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cajka</surname><given-names>T.</given-names></name><name><surname>Fiehn</surname><given-names>O.</given-names></name></person-group>
<article-title>Toward merging untargeted and targeted methods in mass spectrometry-based metabolomics and lipidomics</article-title>
<source>Anal. Chem.</source>
<year>2015</year>
<volume>88</volume>
<fpage>524</fpage>
<lpage>545</lpage>
<pub-id pub-id-type="doi">10.1021/acs.analchem.5b04491</pub-id>
<?supplied-pmid 26637011?><pub-id pub-id-type="pmid">26637011</pub-id></element-citation></ref><ref id="B53-ijms-17-01555"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scherl</surname><given-names>A.</given-names></name></person-group>
<article-title>Clinical protein mass spectrometry</article-title>
<source>Methods</source>
<year>2015</year>
<volume>81</volume>
<fpage>3</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymeth.2015.02.015</pub-id>
<?supplied-pmid 25752846?><pub-id pub-id-type="pmid">25752846</pub-id></element-citation></ref><ref id="B54-ijms-17-01555"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kusebauch</surname><given-names>U.</given-names></name><name><surname>Campbell</surname><given-names>D.S.</given-names></name><name><surname>Deutsch</surname><given-names>E.W.</given-names></name><name><surname>Chu</surname><given-names>C.S.</given-names></name><name><surname>Spicer</surname><given-names>D.A.</given-names></name><name><surname>Brusniak</surname><given-names>M.-Y.</given-names></name><name><surname>Slagel</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Stevens</surname><given-names>J.</given-names></name><name><surname>Grimes</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>Human srmatlas: A resource of targeted assays to quantify the complete human proteome</article-title>
<source>Cell</source>
<year>2016</year>
<volume>166</volume>
<fpage>766</fpage>
<lpage>778</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.06.041</pub-id>
<?supplied-pmid 27453469?><pub-id pub-id-type="pmid">27453469</pub-id></element-citation></ref><ref id="B55-ijms-17-01555"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>May</surname><given-names>J.C.</given-names></name><name><surname>McLean</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Advanced multidimensional separations in mass spectrometry: Navigating the big data deluge</article-title>
<source>Annu. Rev. Anal. Chem.</source>
<year>2016</year>
<volume>9</volume>
<fpage>387</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-anchem-071015-041734</pub-id>
<?supplied-pmid 27306312?><pub-id pub-id-type="pmid">27306312</pub-id></element-citation></ref><ref id="B56-ijms-17-01555"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tebani</surname><given-names>A.</given-names></name><name><surname>Schmitz-Afonso</surname><given-names>I.</given-names></name><name><surname>Rutledge</surname><given-names>D.N.</given-names></name><name><surname>Gonzalez</surname><given-names>B.J.</given-names></name><name><surname>Bekri</surname><given-names>S.</given-names></name><name><surname>Afonso</surname><given-names>C.</given-names></name></person-group>
<article-title>Optimization of a liquid chromatography ion mobility-mass spectrometry method for untargeted metabolomics using experimental design and multivariate data analysis</article-title>
<source>Anal. Chim. Acta</source>
<year>2016</year>
<volume>913</volume>
<fpage>55</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.aca.2016.02.011</pub-id>
<?supplied-pmid 26944989?><pub-id pub-id-type="pmid">26944989</pub-id></element-citation></ref><ref id="B57-ijms-17-01555"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>James</surname><given-names>P.</given-names></name></person-group>
<article-title>Protein identification in the post-genome era: The rapid rise of proteomics</article-title>
<source>Quart. Rev. Biophys.</source>
<year>1997</year>
<volume>30</volume>
<fpage>279</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1017/S0033583597003399</pub-id>
</element-citation></ref><ref id="B58-ijms-17-01555"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khoury</surname><given-names>G.A.</given-names></name><name><surname>Baliban</surname><given-names>R.C.</given-names></name><name><surname>Floudas</surname><given-names>C.A.</given-names></name></person-group>
<article-title>Proteome-wide post-translational modification statistics: Frequency analysis and curation of the swiss-prot database</article-title>
<source>Sci. Rep.</source>
<year>2011</year>
<volume>1</volume>
<fpage>90</fpage>
<pub-id pub-id-type="doi">10.1038/srep00090</pub-id>
<?supplied-pmid 22034591?><pub-id pub-id-type="pmid">22034591</pub-id></element-citation></ref><ref id="B59-ijms-17-01555"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Betzen</surname><given-names>C.</given-names></name><name><surname>Alhamdani</surname><given-names>M.S.S.</given-names></name><name><surname>Lueong</surname><given-names>S.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>C.</given-names></name><name><surname>Stang</surname><given-names>A.</given-names></name><name><surname>Hoheisel</surname><given-names>J.D.</given-names></name></person-group>
<article-title>Clinical proteomics: Promises, challenges and limitations of affinity arrays</article-title>
<source>Proteom. Clin. Appl.</source>
<year>2015</year>
<volume>9</volume>
<fpage>342</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1002/prca.201400156</pub-id>
<?supplied-pmid 25594918?><pub-id pub-id-type="pmid">25594918</pub-id></element-citation></ref><ref id="B60-ijms-17-01555"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sabbagh</surname><given-names>B.</given-names></name><name><surname>Mindt</surname><given-names>S.</given-names></name><name><surname>Neumaier</surname><given-names>M.</given-names></name><name><surname>Findeisen</surname><given-names>P.</given-names></name></person-group>
<article-title>Clinical applications of ms-based protein quantification</article-title>
<source>Proteom. Clin. Appl.</source>
<year>2016</year>
<volume>10</volume>
<fpage>323</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="doi">10.1002/prca.201500116</pub-id>
<?supplied-pmid 27061318?><pub-id pub-id-type="pmid">27061318</pub-id></element-citation></ref><ref id="B61-ijms-17-01555"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lassman</surname><given-names>M.E.</given-names></name><name><surname>McAvoy</surname><given-names>T.</given-names></name><name><surname>Chappell</surname><given-names>D.L.</given-names></name><name><surname>Lee</surname><given-names>A.Y.</given-names></name><name><surname>Zhao</surname><given-names>X.X.</given-names></name><name><surname>Laterza</surname><given-names>O.F.</given-names></name></person-group>
<article-title>The clinical utility of mass spectrometry based protein assays</article-title>
<source>Clin. Chim. Acta</source>
<year>2016</year>
<volume>459</volume>
<fpage>155</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.1016/j.cca.2016.05.027</pub-id>
<?supplied-pmid 27259466?><pub-id pub-id-type="pmid">27259466</pub-id></element-citation></ref><ref id="B62-ijms-17-01555"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovacevic</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Goldfarb</surname><given-names>D.S.</given-names></name><name><surname>Lakshmanan</surname><given-names>Y.</given-names></name><name><surname>Caruso</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Urine proteomic analysis in cystinuric children with renal stones</article-title>
<source>J. Pediatr. Urol.</source>
<year>2015</year>
<volume>11</volume>
<fpage>217.e1</fpage>
<lpage>217.e6</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpurol.2015.04.020</pub-id>
<?supplied-pmid 26076823?><pub-id pub-id-type="pmid">26076823</pub-id></element-citation></ref><ref id="B63-ijms-17-01555"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heywood</surname><given-names>W.E.</given-names></name><name><surname>Camuzeaux</surname><given-names>S.</given-names></name><name><surname>Doykov</surname><given-names>I.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Preece</surname><given-names>R.L.</given-names></name><name><surname>Footitt</surname><given-names>E.</given-names></name><name><surname>Cleary</surname><given-names>M.</given-names></name><name><surname>Clayton</surname><given-names>P.</given-names></name><name><surname>Grunewald</surname><given-names>S.</given-names></name><name><surname>Abulhoul</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>Proteomic discovery and development of a multiplexed targeted mrm-lc-ms/ms assay for urine biomarkers of extracellular matrix disruption in mucopolysaccharidoses I, II, and VI</article-title>
<source>Anal. Chem.</source>
<year>2015</year>
<volume>87</volume>
<fpage>12238</fpage>
<lpage>12244</lpage>
<pub-id pub-id-type="doi">10.1021/acs.analchem.5b03232</pub-id>
<?supplied-pmid 26537538?><pub-id pub-id-type="pmid">26537538</pub-id></element-citation></ref><ref id="B64-ijms-17-01555"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>E.G.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Jha</surname><given-names>P.</given-names></name><name><surname>Dubuis</surname><given-names>S.</given-names></name><name><surname>Blattmann</surname><given-names>P.</given-names></name><name><surname>Argmann</surname><given-names>C.A.</given-names></name><name><surname>Houten</surname><given-names>S.M.</given-names></name><name><surname>Amariuta</surname><given-names>T.</given-names></name><name><surname>Wolski</surname><given-names>W.</given-names></name><name><surname>Zamboni</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Systems proteomics of liver mitochondria function</article-title>
<source>Science</source>
<year>2016</year>
<volume>352</volume>
<fpage>aad0189</fpage>
<pub-id pub-id-type="doi">10.1126/science.aad0189</pub-id>
<?supplied-pmid 27284200?><pub-id pub-id-type="pmid">27284200</pub-id></element-citation></ref><ref id="B65-ijms-17-01555"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martens</surname><given-names>L.</given-names></name></person-group>
<article-title>Bringing proteomics into the clinic: The need for the field to finally take itself seriously</article-title>
<source>Proteom. Clin. Appl.</source>
<year>2013</year>
<volume>7</volume>
<fpage>388</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1002/prca.201300020</pub-id>
<?supplied-pmid 23637000?><pub-id pub-id-type="pmid">23637000</pub-id></element-citation></ref><ref id="B66-ijms-17-01555"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holmes</surname><given-names>E.</given-names></name><name><surname>Wilson</surname><given-names>I.D.</given-names></name><name><surname>Nicholson</surname><given-names>J.K.</given-names></name></person-group>
<article-title>Metabolic phenotyping in health and disease</article-title>
<source>Cell</source>
<year>2008</year>
<volume>134</volume>
<fpage>714</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.08.026</pub-id>
<?supplied-pmid 18775301?><pub-id pub-id-type="pmid">18775301</pub-id></element-citation></ref><ref id="B67-ijms-17-01555"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oliver</surname><given-names>S.G.</given-names></name><name><surname>Winson</surname><given-names>M.K.</given-names></name><name><surname>Kell</surname><given-names>D.B.</given-names></name><name><surname>Baganz</surname><given-names>F.</given-names></name></person-group>
<article-title>Systematic functional analysis of the yeast genome</article-title>
<source>Trends Biotechnol.</source>
<year>1998</year>
<volume>16</volume>
<fpage>373</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-7799(98)01214-1</pub-id>
<pub-id pub-id-type="pmid">9744112</pub-id></element-citation></ref><ref id="B68-ijms-17-01555"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>J.K.</given-names></name><name><surname>Lindon</surname><given-names>J.C.</given-names></name><name><surname>Holmes</surname><given-names>E.</given-names></name></person-group>
<article-title>&#x0201c;Metabonomics&#x0201d;: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data</article-title>
<source>Xenobiotica</source>
<year>1999</year>
<volume>29</volume>
<fpage>1181</fpage>
<lpage>1189</lpage>
<pub-id pub-id-type="doi">10.1080/004982599238047</pub-id>
<?supplied-pmid 10598751?><pub-id pub-id-type="pmid">10598751</pub-id></element-citation></ref><ref id="B69-ijms-17-01555"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>J.K.</given-names></name><name><surname>Holmes</surname><given-names>E.</given-names></name><name><surname>Kinross</surname><given-names>J.M.</given-names></name><name><surname>Darzi</surname><given-names>A.W.</given-names></name><name><surname>Takats</surname><given-names>Z.</given-names></name><name><surname>Lindon</surname><given-names>J.C.</given-names></name></person-group>
<article-title>Metabolic phenotyping in clinical and surgical environments</article-title>
<source>Nature</source>
<year>2012</year>
<volume>491</volume>
<fpage>384</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="doi">10.1038/nature11708</pub-id>
<?supplied-pmid 23151581?><pub-id pub-id-type="pmid">23151581</pub-id></element-citation></ref><ref id="B70-ijms-17-01555"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suhre</surname><given-names>K.</given-names></name><name><surname>Raffler</surname><given-names>J.</given-names></name><name><surname>Kastenm&#x000fc;ller</surname><given-names>G.</given-names></name></person-group>
<article-title>Biochemical insights from population studies with genetics and metabolomics</article-title>
<source>Arch. Biochem. Biophys.</source>
<year>2016</year>
<volume>589</volume>
<fpage>168</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1016/j.abb.2015.09.023</pub-id>
<?supplied-pmid 26432701?><pub-id pub-id-type="pmid">26432701</pub-id></element-citation></ref><ref id="B71-ijms-17-01555"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A.</given-names></name><name><surname>Marsal</surname><given-names>S.</given-names></name><name><surname>Julia</surname><given-names>A.</given-names></name></person-group>
<article-title>Analytical methods in untargeted metabolomics: State of the art in 2015</article-title>
<source>Front. Bioeng. Biotechnol.</source>
<year>2015</year>
<volume>3</volume>
<fpage>23</fpage>
<pub-id pub-id-type="doi">10.3389/fbioe.2015.00023</pub-id>
<?supplied-pmid 25798438?><pub-id pub-id-type="pmid">25798438</pub-id></element-citation></ref><ref id="B72-ijms-17-01555"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Therrell</surname><given-names>B.L.</given-names></name><name><surname>Padilla</surname><given-names>C.D.</given-names></name><name><surname>Loeber</surname><given-names>J.G.</given-names></name><name><surname>Kneisser</surname><given-names>I.</given-names></name><name><surname>Saadallah</surname><given-names>A.</given-names></name><name><surname>Borrajo</surname><given-names>G.J.</given-names></name><name><surname>Adams</surname><given-names>J.</given-names></name></person-group>
<article-title>Current status of newborn screening worldwide: 2015</article-title>
<source>Semin. Perinatol.</source>
<year>2015</year>
<volume>39</volume>
<fpage>171</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1053/j.semperi.2015.03.002</pub-id>
<?supplied-pmid 25979780?><pub-id pub-id-type="pmid">25979780</pub-id></element-citation></ref><ref id="B73-ijms-17-01555"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Denes</surname><given-names>J.</given-names></name><name><surname>Szabo</surname><given-names>E.</given-names></name><name><surname>Robinette</surname><given-names>S.L.</given-names></name><name><surname>Szatmari</surname><given-names>I.</given-names></name><name><surname>Szonyi</surname><given-names>L.</given-names></name><name><surname>Kreuder</surname><given-names>J.G.</given-names></name><name><surname>Rauterberg</surname><given-names>E.W.</given-names></name><name><surname>Takats</surname><given-names>Z.</given-names></name></person-group>
<article-title>Metabonomics of newborn screening dried blood spot samples: A novel approach in the screening and diagnostics of inborn errors of metabolism</article-title>
<source>Anal. Chem.</source>
<year>2012</year>
<volume>84</volume>
<fpage>10113</fpage>
<lpage>10120</lpage>
<pub-id pub-id-type="doi">10.1021/ac302527m</pub-id>
<?supplied-pmid 23094949?><pub-id pub-id-type="pmid">23094949</pub-id></element-citation></ref><ref id="B74-ijms-17-01555"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aygen</surname><given-names>S.</given-names></name><name><surname>Durr</surname><given-names>U.</given-names></name><name><surname>Hegele</surname><given-names>P.</given-names></name><name><surname>Kunig</surname><given-names>J.</given-names></name><name><surname>Spraul</surname><given-names>M.</given-names></name><name><surname>Schafer</surname><given-names>H.</given-names></name><name><surname>Krings</surname><given-names>D.</given-names></name><name><surname>Cannet</surname><given-names>C.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Schutz</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>NMR-based screening for inborn errors of metabolism: Initial results from a study on turkish neonates</article-title>
<source>JIMD Rep.</source>
<year>2014</year>
<volume>16</volume>
<fpage>101</fpage>
<lpage>111</lpage>
<?supplied-pmid 25012580?><pub-id pub-id-type="pmid">25012580</pub-id></element-citation></ref><ref id="B75-ijms-17-01555"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Kennedy</surname><given-names>A.</given-names></name><name><surname>Eckhart</surname><given-names>A.</given-names></name><name><surname>Burrage</surname><given-names>L.</given-names></name><name><surname>Wulff</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>L.D.</given-names></name><name><surname>Milburn</surname><given-names>M.</given-names></name><name><surname>Ryals</surname><given-names>J.</given-names></name><name><surname>Beaudet</surname><given-names>A.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><etal/></person-group>
<article-title>Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism</article-title>
<source>J. Inherit. Metab. Dis.</source>
<year>2015</year>
<volume>38</volume>
<fpage>1029</fpage>
<lpage>1039</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-015-9843-7</pub-id>
<?supplied-pmid 25875217?><pub-id pub-id-type="pmid">25875217</pub-id></element-citation></ref><ref id="B76-ijms-17-01555"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tebani</surname><given-names>A.</given-names></name><name><surname>Abily-Donval</surname><given-names>L.</given-names></name><name><surname>Afonso</surname><given-names>C.</given-names></name><name><surname>Marret</surname><given-names>S.</given-names></name><name><surname>Bekri</surname><given-names>S.</given-names></name></person-group>
<article-title>Clinical metabolomics: The new metabolic window for inborn errors of metabolism investigations in the post-genomic era</article-title>
<source>Int. J. Mol. Sci.</source>
<year>2016</year>
<volume>17</volume>
<fpage>1167</fpage>
<pub-id pub-id-type="doi">10.3390/ijms17071167</pub-id>
<?supplied-pmid 27447622?><pub-id pub-id-type="pmid">27447622</pub-id></element-citation></ref><ref id="B77-ijms-17-01555"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Houle</surname><given-names>D.</given-names></name><name><surname>Govindaraju</surname><given-names>D.R.</given-names></name><name><surname>Omholt</surname><given-names>S.</given-names></name></person-group>
<article-title>Phenomics: The next challenge</article-title>
<source>Nat. Rev. Genet.</source>
<year>2010</year>
<volume>11</volume>
<fpage>855</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2897</pub-id>
<?supplied-pmid 21085204?><pub-id pub-id-type="pmid">21085204</pub-id></element-citation></ref><ref id="B78-ijms-17-01555"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plomin</surname><given-names>R.</given-names></name><name><surname>Haworth</surname><given-names>C.M.</given-names></name><name><surname>Davis</surname><given-names>O.S.</given-names></name></person-group>
<article-title>Common disorders are quantitative traits</article-title>
<source>Nat. Rev. Genet.</source>
<year>2009</year>
<volume>10</volume>
<fpage>872</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2670</pub-id>
<?supplied-pmid 19859063?><pub-id pub-id-type="pmid">19859063</pub-id></element-citation></ref><ref id="B79-ijms-17-01555"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bush</surname><given-names>W.S.</given-names></name><name><surname>Oetjens</surname><given-names>M.T.</given-names></name><name><surname>Crawford</surname><given-names>D.C.</given-names></name></person-group>
<article-title>Unravelling the human genome-phenome relationship using phenome-wide association studies</article-title>
<source>Nat. Rev. Genet.</source>
<year>2016</year>
<volume>17</volume>
<fpage>129</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1038/nrg.2015.36</pub-id>
<?supplied-pmid 26875678?><pub-id pub-id-type="pmid">26875678</pub-id></element-citation></ref><ref id="B80-ijms-17-01555"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bilder</surname><given-names>R.M.</given-names></name><name><surname>Sabb</surname><given-names>F.W.</given-names></name><name><surname>Cannon</surname><given-names>T.D.</given-names></name><name><surname>London</surname><given-names>E.D.</given-names></name><name><surname>Jentsch</surname><given-names>J.D.</given-names></name><name><surname>Parker</surname><given-names>D.S.</given-names></name><name><surname>Poldrack</surname><given-names>R.A.</given-names></name><name><surname>Evans</surname><given-names>C.</given-names></name><name><surname>Freimer</surname><given-names>N.B.</given-names></name></person-group>
<article-title>Phenomics: The systematic study of phenotypes on a genome-wide scale</article-title>
<source>Neuroscience</source>
<year>2009</year>
<volume>164</volume>
<fpage>30</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.01.027</pub-id>
<?supplied-pmid 19344640?><pub-id pub-id-type="pmid">19344640</pub-id></element-citation></ref><ref id="B81-ijms-17-01555"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freimer</surname><given-names>N.</given-names></name><name><surname>Sabatti</surname><given-names>C.</given-names></name></person-group>
<article-title>The human phenome project</article-title>
<source>Nat. Genet.</source>
<year>2003</year>
<volume>34</volume>
<fpage>15</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1038/ng0503-15</pub-id>
<?supplied-pmid 12721547?><pub-id pub-id-type="pmid">12721547</pub-id></element-citation></ref><ref id="B82-ijms-17-01555"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerlai</surname><given-names>R.</given-names></name></person-group>
<article-title>Phenomics: Fiction or the future?</article-title>
<source>Trends Neurosci.</source>
<year>2002</year>
<volume>25</volume>
<fpage>506</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-2236(02)02250-6</pub-id>
<pub-id pub-id-type="pmid">12220878</pub-id></element-citation></ref><ref id="B83-ijms-17-01555"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oetting</surname><given-names>W.S.</given-names></name><name><surname>Robinson</surname><given-names>P.N.</given-names></name><name><surname>Greenblatt</surname><given-names>M.S.</given-names></name><name><surname>Cotton</surname><given-names>R.G.</given-names></name><name><surname>Beck</surname><given-names>T.</given-names></name><name><surname>Carey</surname><given-names>J.C.</given-names></name><name><surname>Doelken</surname><given-names>S.C.</given-names></name><name><surname>Girdea</surname><given-names>M.</given-names></name><name><surname>Groza</surname><given-names>T.</given-names></name><name><surname>Hamilton</surname><given-names>C.M.</given-names></name><etal/></person-group>
<article-title>Getting ready for the human phenome project: The 2012 forum of the human variome project</article-title>
<source>Hum. Mutat.</source>
<year>2013</year>
<volume>34</volume>
<fpage>661</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22293</pub-id>
<?supplied-pmid 23401191?><pub-id pub-id-type="pmid">23401191</pub-id></element-citation></ref><ref id="B84-ijms-17-01555"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groza</surname><given-names>T.</given-names></name><name><surname>Kohler</surname><given-names>S.</given-names></name><name><surname>Moldenhauer</surname><given-names>D.</given-names></name><name><surname>Vasilevsky</surname><given-names>N.</given-names></name><name><surname>Baynam</surname><given-names>G.</given-names></name><name><surname>Zemojtel</surname><given-names>T.</given-names></name><name><surname>Schriml</surname><given-names>L.M.</given-names></name><name><surname>Kibbe</surname><given-names>W.A.</given-names></name><name><surname>Schofield</surname><given-names>P.N.</given-names></name><name><surname>Beck</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>The human phenotype ontology: Semantic unification of common and rare disease</article-title>
<source>Am. J. Hum. Genet.</source>
<year>2015</year>
<volume>97</volume>
<fpage>111</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.05.020</pub-id>
<?supplied-pmid 26119816?><pub-id pub-id-type="pmid">26119816</pub-id></element-citation></ref><ref id="B85-ijms-17-01555"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>M.D.</given-names></name><name><surname>Holzinger</surname><given-names>E.R.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Pendergrass</surname><given-names>S.A.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name></person-group>
<article-title>Methods of integrating data to uncover genotype-phenotype interactions</article-title>
<source>Nat. Rev. Genet.</source>
<year>2015</year>
<volume>16</volume>
<fpage>85</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3868</pub-id>
<?supplied-pmid 25582081?><pub-id pub-id-type="pmid">25582081</pub-id></element-citation></ref><ref id="B86-ijms-17-01555"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tracy</surname><given-names>R.P.</given-names></name></person-group>
<article-title>&#x0201c;Deep phenotyping&#x0201d;: Characterizing populations in the era of genomics and systems biology</article-title>
<source>Curr. Opin. Lipidol.</source>
<year>2008</year>
<volume>19</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1097/MOL.0b013e3282f73893</pub-id>
<?supplied-pmid 18388695?><pub-id pub-id-type="pmid">18388695</pub-id></element-citation></ref><ref id="B87-ijms-17-01555"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Badgeley</surname><given-names>M.A.</given-names></name><name><surname>Miotto</surname><given-names>R.</given-names></name><name><surname>Glicksberg</surname><given-names>B.S.</given-names></name><name><surname>Morgan</surname><given-names>J.W.</given-names></name><name><surname>Dudley</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Translational bioinformatics in the era of real-time biomedical, health care and wellness data streams</article-title>
<source>Brief. Bioinform.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1093/bib/bbv118</pub-id>
<?supplied-pmid 26876889?><pub-id pub-id-type="pmid">26876889</pub-id></element-citation></ref><ref id="B88-ijms-17-01555"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kochinke</surname><given-names>K.</given-names></name><name><surname>Zweier</surname><given-names>C.</given-names></name><name><surname>Nijhof</surname><given-names>B.</given-names></name><name><surname>Fenckova</surname><given-names>M.</given-names></name><name><surname>Cizek</surname><given-names>P.</given-names></name><name><surname>Honti</surname><given-names>F.</given-names></name><name><surname>Keerthikumar</surname><given-names>S.</given-names></name><name><surname>Oortveld Merel</surname><given-names>A.W.</given-names></name><name><surname>Kleefstra</surname><given-names>T.</given-names></name><name><surname>Kramer</surname><given-names>J.M.</given-names></name><etal/></person-group>
<article-title>Systematic phenomics analysis deconvolutes genes mutated in intellectual disability into biologically coherent modules</article-title>
<source>Am. J. Hum. Genet.</source>
<year>2016</year>
<volume>98</volume>
<fpage>149</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.11.024</pub-id>
<?supplied-pmid 26748517?><pub-id pub-id-type="pmid">26748517</pub-id></element-citation></ref><ref id="B89-ijms-17-01555"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Herazo-Maya</surname><given-names>J.D.</given-names></name><name><surname>Kang</surname><given-names>D.D.</given-names></name><name><surname>Juan-Guardela</surname><given-names>B.M.</given-names></name><name><surname>Tedrow</surname><given-names>J.</given-names></name><name><surname>Martinez</surname><given-names>F.J.</given-names></name><name><surname>Sciurba</surname><given-names>F.C.</given-names></name><name><surname>Tseng</surname><given-names>G.C.</given-names></name><name><surname>Kaminski</surname><given-names>N.</given-names></name></person-group>
<article-title>Integrative phenotyping framework (iPF): Integrative clustering of multiple omics data identifies novel lung disease subphenotypes</article-title>
<source>BMC Genom.</source>
<year>2015</year>
<volume>16</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1186/1755-8794-8-S2-I1</pub-id>
<?supplied-pmid 26043981?><pub-id pub-id-type="pmid">26043981</pub-id></element-citation></ref><ref id="B90-ijms-17-01555"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mungall</surname><given-names>C.J.</given-names></name><name><surname>Washington</surname><given-names>N.L.</given-names></name><name><surname>Nguyen-Xuan</surname><given-names>J.</given-names></name><name><surname>Condit</surname><given-names>C.</given-names></name><name><surname>Smedley</surname><given-names>D.</given-names></name><name><surname>Kohler</surname><given-names>S.</given-names></name><name><surname>Groza</surname><given-names>T.</given-names></name><name><surname>Shefchek</surname><given-names>K.</given-names></name><name><surname>Hochheiser</surname><given-names>H.</given-names></name><name><surname>Robinson</surname><given-names>P.N.</given-names></name><etal/></person-group>
<article-title>Use of model organism and disease databases to support matchmaking for human disease gene discovery</article-title>
<source>Hum. Mutat.</source>
<year>2015</year>
<volume>36</volume>
<fpage>979</fpage>
<lpage>984</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22857</pub-id>
<?supplied-pmid 26269093?><pub-id pub-id-type="pmid">26269093</pub-id></element-citation></ref><ref id="B91-ijms-17-01555"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Argmann</surname><given-names>C.A.</given-names></name><name><surname>Houten</surname><given-names>S.M.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Schadt</surname><given-names>E.E.</given-names></name></person-group>
<article-title>A next generation multiscale view of inborn errors of metabolism</article-title>
<source>Cell Metab.</source>
<year>2016</year>
<volume>23</volume>
<fpage>13</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2015.11.012</pub-id>
<?supplied-pmid 26712461?><pub-id pub-id-type="pmid">26712461</pub-id></element-citation></ref><ref id="B92-ijms-17-01555"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gligorijevic</surname><given-names>V.</given-names></name><name><surname>Przulj</surname><given-names>N.</given-names></name></person-group>
<article-title>Methods for biological data integration: Perspectives and challenges</article-title>
<source>J. R. Soc. Interface</source>
<year>2015</year>
<volume>12</volume>
<fpage>112</fpage>
<pub-id pub-id-type="doi">10.1098/rsif.2015.0571</pub-id>
<?supplied-pmid 26490630?><pub-id pub-id-type="pmid">26490630</pub-id></element-citation></ref><ref id="B93-ijms-17-01555"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wanichthanarak</surname><given-names>K.</given-names></name><name><surname>Fahrmann</surname><given-names>J.F.</given-names></name><name><surname>Grapov</surname><given-names>D.</given-names></name></person-group>
<article-title>Genomic, proteomic, and metabolomic data integration strategies</article-title>
<source>Biomark. Insights</source>
<year>2015</year>
<volume>10</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<?supplied-pmid 26396492?><pub-id pub-id-type="pmid">26396492</pub-id></element-citation></ref><ref id="B94-ijms-17-01555"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wahl</surname><given-names>S.</given-names></name><name><surname>Vogt</surname><given-names>S.</given-names></name><name><surname>Stuckler</surname><given-names>F.</given-names></name><name><surname>Krumsiek</surname><given-names>J.</given-names></name><name><surname>Bartel</surname><given-names>J.</given-names></name><name><surname>Kacprowski</surname><given-names>T.</given-names></name><name><surname>Schramm</surname><given-names>K.</given-names></name><name><surname>Carstensen</surname><given-names>M.</given-names></name><name><surname>Rathmann</surname><given-names>W.</given-names></name><name><surname>Roden</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Multi-omic signature of body weight change: Results from a population-based cohort study</article-title>
<source>BMC Med.</source>
<year>2015</year>
<volume>13</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12916-015-0282-y</pub-id>
<?supplied-pmid 25857605?><pub-id pub-id-type="pmid">25857605</pub-id></element-citation></ref><ref id="B95-ijms-17-01555"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group>
<article-title>Topologically inferring pathway activity toward precise cancer classification via integrating genomic and metabolomic data: Prostate cancer as a case</article-title>
<source>Sci. Rep.</source>
<year>2015</year>
<volume>5</volume>
<fpage>13192</fpage>
<pub-id pub-id-type="doi">10.1038/srep13192</pub-id>
<?supplied-pmid 26286638?><pub-id pub-id-type="pmid">26286638</pub-id></element-citation></ref><ref id="B96-ijms-17-01555"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Mias</surname><given-names>G.I.</given-names></name><name><surname>Li-Pook-Than</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Lam</surname><given-names>H.Y.K.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Miriami</surname><given-names>E.</given-names></name><name><surname>Karczewski</surname><given-names>K.J.</given-names></name><name><surname>Hariharan</surname><given-names>M.</given-names></name><name><surname>Dewey</surname><given-names>F.E.</given-names></name><etal/></person-group>
<article-title>Personal omics profiling reveals dynamic molecular and medical phenotypes</article-title>
<source>Cell</source>
<year>2012</year>
<volume>148</volume>
<fpage>1293</fpage>
<lpage>1307</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.02.009</pub-id>
<?supplied-pmid 22424236?><pub-id pub-id-type="pmid">22424236</pub-id></element-citation></ref><ref id="B97-ijms-17-01555"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartel</surname><given-names>J.</given-names></name><name><surname>Krumsiek</surname><given-names>J.</given-names></name><name><surname>Schramm</surname><given-names>K.</given-names></name><name><surname>Adamski</surname><given-names>J.</given-names></name><name><surname>Gieger</surname><given-names>C.</given-names></name><name><surname>Herder</surname><given-names>C.</given-names></name><name><surname>Carstensen</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>A.</given-names></name><name><surname>Rathmann</surname><given-names>W.</given-names></name><name><surname>Roden</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>The human blood metabolome-transcriptome interface</article-title>
<source>PLoS Genet.</source>
<year>2015</year>
<volume>11</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1005274</pub-id>
<?supplied-pmid 26086077?><pub-id pub-id-type="pmid">26086077</pub-id></element-citation></ref><ref id="B98-ijms-17-01555"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shin</surname><given-names>S.Y.</given-names></name><name><surname>Fauman</surname><given-names>E.B.</given-names></name><name><surname>Petersen</surname><given-names>A.K.</given-names></name><name><surname>Krumsiek</surname><given-names>J.</given-names></name><name><surname>Santos</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Arnold</surname><given-names>M.</given-names></name><name><surname>Erte</surname><given-names>I.</given-names></name><name><surname>Forgetta</surname><given-names>V.</given-names></name><name><surname>Yang</surname><given-names>T.P.</given-names></name><etal/></person-group>
<article-title>An atlas of genetic influences on human blood metabolites</article-title>
<source>Nat. Genet.</source>
<year>2014</year>
<volume>46</volume>
<fpage>543</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2982</pub-id>
<?supplied-pmid 24816252?><pub-id pub-id-type="pmid">24816252</pub-id></element-citation></ref><ref id="B99-ijms-17-01555"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petersen</surname><given-names>A.K.</given-names></name><name><surname>Zeilinger</surname><given-names>S.</given-names></name><name><surname>Kastenmuller</surname><given-names>G.</given-names></name><name><surname>Romisch-Margl</surname><given-names>W.</given-names></name><name><surname>Brugger</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>A.</given-names></name><name><surname>Meisinger</surname><given-names>C.</given-names></name><name><surname>Strauch</surname><given-names>K.</given-names></name><name><surname>Hengstenberg</surname><given-names>C.</given-names></name><name><surname>Pagel</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>Epigenetics meets metabolomics: An epigenome-wide association study with blood serum metabolic traits</article-title>
<source>Hum. Mol. Genet.</source>
<year>2014</year>
<volume>23</volume>
<fpage>534</fpage>
<lpage>545</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt430</pub-id>
<?supplied-pmid 24014485?><pub-id pub-id-type="pmid">24014485</pub-id></element-citation></ref><ref id="B100-ijms-17-01555"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>J.P.</given-names></name><name><surname>Khoury</surname><given-names>M.J.</given-names></name></person-group>
<article-title>Improving validation practices in &#x0201c;omics&#x0201d; research</article-title>
<source>Science</source>
<year>2011</year>
<volume>334</volume>
<fpage>1230</fpage>
<lpage>1232</lpage>
<pub-id pub-id-type="doi">10.1126/science.1211811</pub-id>
<?supplied-pmid 22144616?><pub-id pub-id-type="pmid">22144616</pub-id></element-citation></ref><ref id="B101-ijms-17-01555"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolker</surname><given-names>E.</given-names></name><name><surname>Ozdemir</surname><given-names>V.</given-names></name><name><surname>Martens</surname><given-names>L.</given-names></name><name><surname>Hancock</surname><given-names>W.</given-names></name><name><surname>Anderson</surname><given-names>G.</given-names></name><name><surname>Anderson</surname><given-names>N.</given-names></name><name><surname>Aynacioglu</surname><given-names>S.</given-names></name><name><surname>Baranova</surname><given-names>A.</given-names></name><name><surname>Campagna</surname><given-names>S.R.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>Toward more transparent and reproducible omics studies through a common metadata checklist and data publications</article-title>
<source>Omics</source>
<year>2014</year>
<volume>18</volume>
<fpage>10</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1089/omi.2013.0149</pub-id>
<?supplied-pmid 24456465?><pub-id pub-id-type="pmid">24456465</pub-id></element-citation></ref><ref id="B102-ijms-17-01555"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tenenbaum</surname><given-names>J.D.</given-names></name><name><surname>Sansone</surname><given-names>S.A.</given-names></name><name><surname>Haendel</surname><given-names>M.</given-names></name></person-group>
<article-title>A sea of standards for omics data: Sink or swim?</article-title>
<source>JAMIA</source>
<year>2014</year>
<volume>21</volume>
<fpage>200</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1136/amiajnl-2013-002066</pub-id>
<?supplied-pmid 24076747?><pub-id pub-id-type="pmid">24076747</pub-id></element-citation></ref><ref id="B103-ijms-17-01555"><label>103.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Chitayat</surname><given-names>S.</given-names></name><name><surname>Rudan</surname><given-names>J.F.</given-names></name></person-group>
<article-title>Chapter 10&#x02014;Phenome centers and global harmonization</article-title>
<source>Metabolic Phenotyping in Personalized and Public Healthcare</source>
<publisher-name>Academic Press</publisher-name>
<publisher-loc>Boston, MA, USA</publisher-loc>
<year>2016</year>
<fpage>291</fpage>
<lpage>315</lpage>
</element-citation></ref><ref id="B104-ijms-17-01555"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rocca-Serra</surname><given-names>P.</given-names></name><name><surname>Salek</surname><given-names>R.M.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Correa</surname><given-names>E.</given-names></name><name><surname>Dayalan</surname><given-names>S.</given-names></name><name><surname>Gonzalez-Beltran</surname><given-names>A.</given-names></name><name><surname>Ebbels</surname><given-names>T.</given-names></name><name><surname>Goodacre</surname><given-names>R.</given-names></name><name><surname>Hastings</surname><given-names>J.</given-names></name><name><surname>Haug</surname><given-names>K.</given-names></name><etal/></person-group>
<article-title>Data standards can boost metabolomics research, and if there is a will, there is a way</article-title>
<source>Metabolomics</source>
<year>2016</year>
<volume>12</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.1007/s11306-015-0879-3</pub-id>
<?supplied-pmid 26612985?><pub-id pub-id-type="pmid">26612985</pub-id></element-citation></ref><ref id="B105-ijms-17-01555"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dunn</surname><given-names>W.B.</given-names></name><name><surname>Wilson</surname><given-names>I.D.</given-names></name><name><surname>Nicholls</surname><given-names>A.W.</given-names></name><name><surname>Broadhurst</surname><given-names>D.</given-names></name></person-group>
<article-title>The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans</article-title>
<source>Bioanalysis</source>
<year>2012</year>
<volume>4</volume>
<fpage>2249</fpage>
<lpage>2264</lpage>
<pub-id pub-id-type="doi">10.4155/bio.12.204</pub-id>
<?supplied-pmid 23046267?><pub-id pub-id-type="pmid">23046267</pub-id></element-citation></ref><ref id="B106-ijms-17-01555"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walzer</surname><given-names>M.</given-names></name><name><surname>Pernas</surname><given-names>L.E.</given-names></name><name><surname>Nasso</surname><given-names>S.</given-names></name><name><surname>Bittremieux</surname><given-names>W.</given-names></name><name><surname>Nahnsen</surname><given-names>S.</given-names></name><name><surname>Kelchtermans</surname><given-names>P.</given-names></name><name><surname>Pichler</surname><given-names>P.</given-names></name><name><surname>van den Toorn</surname><given-names>H.W.</given-names></name><name><surname>Staes</surname><given-names>A.</given-names></name><name><surname>Vandenbussche</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Qcml: An exchange format for quality control metrics from mass spectrometry experiments</article-title>
<source>Mol. Cell. Proteom.</source>
<year>2014</year>
<volume>13</volume>
<fpage>1905</fpage>
<lpage>1913</lpage>
<pub-id pub-id-type="doi">10.1074/mcp.M113.035907</pub-id>
<?supplied-pmid 24760958?><pub-id pub-id-type="pmid">24760958</pub-id></element-citation></ref><ref id="B107-ijms-17-01555"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Issaq</surname><given-names>H.J.</given-names></name><name><surname>Waybright</surname><given-names>T.J.</given-names></name><name><surname>Veenstra</surname><given-names>T.D.</given-names></name></person-group>
<article-title>Cancer biomarker discovery: Opportunities and pitfalls in analytical methods</article-title>
<source>Electrophoresis</source>
<year>2011</year>
<volume>32</volume>
<fpage>967</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="doi">10.1002/elps.201000588</pub-id>
<?supplied-pmid 21449066?><pub-id pub-id-type="pmid">21449066</pub-id></element-citation></ref><ref id="B108-ijms-17-01555"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>P.</given-names></name><name><surname>Wuolikainen</surname><given-names>A.</given-names></name><name><surname>Thysell</surname><given-names>E.</given-names></name><name><surname>Chorell</surname><given-names>E.</given-names></name><name><surname>Stattin</surname><given-names>P.</given-names></name><name><surname>Wikstrom</surname><given-names>P.</given-names></name><name><surname>Antti</surname><given-names>H.</given-names></name></person-group>
<article-title>Constrained randomization and multivariate effect projections improve information extraction and biomarker pattern discovery in metabolomics studies involving dependent samples</article-title>
<source>Metabolomics</source>
<year>2015</year>
<volume>11</volume>
<fpage>1667</fpage>
<lpage>1678</lpage>
<pub-id pub-id-type="doi">10.1007/s11306-015-0818-3</pub-id>
<?supplied-pmid 26491420?><pub-id pub-id-type="pmid">26491420</pub-id></element-citation></ref><ref id="B109-ijms-17-01555"><label>109.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Scherer</surname><given-names>A.</given-names></name></person-group>
<source>Batch Effects and Noise in Microarray Experiments: Sources and Solutions</source>
<publisher-name>John Wiley &#x00026; Sons</publisher-name>
<publisher-loc>Chichester, UK</publisher-loc>
<year>2009</year>
<volume>Volume 868</volume>
</element-citation></ref><ref id="B110-ijms-17-01555"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vivian</surname><given-names>J.</given-names></name><name><surname>Rao</surname><given-names>A.</given-names></name><name><surname>Nothaft</surname><given-names>F.A.</given-names></name><name><surname>Ketchum</surname><given-names>C.</given-names></name><name><surname>Armstrong</surname><given-names>J.</given-names></name><name><surname>Novak</surname><given-names>A.</given-names></name><name><surname>Pfeil</surname><given-names>J.</given-names></name><name><surname>Narkizian</surname><given-names>J.</given-names></name><name><surname>Deran</surname><given-names>A.D.</given-names></name><name><surname>Musselman-Brown</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Rapid and efficient analysis of 20,000 RNA-Seq samples with toil</article-title>
<source>bioRxiv</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1101/062497</pub-id>
</element-citation></ref><ref id="B111-ijms-17-01555"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Church</surname><given-names>D.M.</given-names></name><name><surname>Schneider</surname><given-names>V.A.</given-names></name><name><surname>Steinberg</surname><given-names>K.M.</given-names></name><name><surname>Schatz</surname><given-names>M.C.</given-names></name><name><surname>Quinlan</surname><given-names>A.R.</given-names></name><name><surname>Chin</surname><given-names>C.-S.</given-names></name><name><surname>Kitts</surname><given-names>P.A.</given-names></name><name><surname>Aken</surname><given-names>B.</given-names></name><name><surname>Marth</surname><given-names>G.T.</given-names></name><name><surname>Hoffman</surname><given-names>M.M.</given-names></name><etal/></person-group>
<article-title>Extending reference assembly models</article-title>
<source>Genome Biol.</source>
<year>2015</year>
<volume>16</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1186/s13059-015-0587-3</pub-id>
<?supplied-pmid 25651527?><pub-id pub-id-type="pmid">25583448</pub-id></element-citation></ref><ref id="B112-ijms-17-01555"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldfeder</surname><given-names>R.L.</given-names></name><name><surname>Priest</surname><given-names>J.R.</given-names></name><name><surname>Zook</surname><given-names>J.M.</given-names></name><name><surname>Grove</surname><given-names>M.E.</given-names></name><name><surname>Waggott</surname><given-names>D.</given-names></name><name><surname>Wheeler</surname><given-names>M.T.</given-names></name><name><surname>Salit</surname><given-names>M.</given-names></name><name><surname>Ashley</surname><given-names>E.A.</given-names></name></person-group>
<article-title>Medical implications of technical accuracy in genome sequencing</article-title>
<source>Genome Med.</source>
<year>2016</year>
<volume>8</volume>
<fpage>24</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-016-0269-0</pub-id>
<?supplied-pmid 26932475?><pub-id pub-id-type="pmid">26932475</pub-id></element-citation></ref><ref id="B113-ijms-17-01555"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tewhey</surname><given-names>R.</given-names></name><name><surname>Bansal</surname><given-names>V.</given-names></name><name><surname>Torkamani</surname><given-names>A.</given-names></name><name><surname>Topol</surname><given-names>E.J.</given-names></name><name><surname>Schork</surname><given-names>N.J.</given-names></name></person-group>
<article-title>The importance of phase information for human genomics</article-title>
<source>Nat. Rev. Genet.</source>
<year>2011</year>
<volume>12</volume>
<fpage>215</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2950</pub-id>
<?supplied-pmid 21301473?><pub-id pub-id-type="pmid">21301473</pub-id></element-citation></ref><ref id="B114-ijms-17-01555"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>G.X.</given-names></name><name><surname>Lau</surname><given-names>B.T.</given-names></name><name><surname>Schnall-Levin</surname><given-names>M.</given-names></name><name><surname>Jarosz</surname><given-names>M.</given-names></name><name><surname>Bell</surname><given-names>J.M.</given-names></name><name><surname>Hindson</surname><given-names>C.M.</given-names></name><name><surname>Kyriazopoulou-Panagiotopoulou</surname><given-names>S.</given-names></name><name><surname>Masquelier</surname><given-names>D.A.</given-names></name><name><surname>Merrill</surname><given-names>L.</given-names></name><name><surname>Terry</surname><given-names>J.M.</given-names></name><etal/></person-group>
<article-title>Haplotyping germline and cancer genomes with high-throughput linked-read sequencing</article-title>
<source>Nat. Biotechnol.</source>
<year>2016</year>
<volume>34</volume>
<fpage>303</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3432</pub-id>
<?supplied-pmid 26829319?><pub-id pub-id-type="pmid">26829319</pub-id></element-citation></ref><ref id="B115-ijms-17-01555"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaisson</surname><given-names>M.J.</given-names></name><name><surname>Huddleston</surname><given-names>J.</given-names></name><name><surname>Dennis</surname><given-names>M.Y.</given-names></name><name><surname>Sudmant</surname><given-names>P.H.</given-names></name><name><surname>Malig</surname><given-names>M.</given-names></name><name><surname>Hormozdiari</surname><given-names>F.</given-names></name><name><surname>Antonacci</surname><given-names>F.</given-names></name><name><surname>Surti</surname><given-names>U.</given-names></name><name><surname>Sandstrom</surname><given-names>R.</given-names></name><name><surname>Boitano</surname><given-names>M.</given-names></name></person-group>
<article-title>Resolving the complexity of the human genome using single-molecule sequencing</article-title>
<source>Nature</source>
<year>2015</year>
<volume>517</volume>
<fpage>608</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="doi">10.1038/nature13907</pub-id>
<?supplied-pmid 25383537?><pub-id pub-id-type="pmid">25383537</pub-id></element-citation></ref><ref id="B116-ijms-17-01555"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foquet</surname><given-names>M.</given-names></name><name><surname>Samiee</surname><given-names>K.T.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Chauduri</surname><given-names>B.P.</given-names></name><name><surname>Lundquist</surname><given-names>P.M.</given-names></name><name><surname>Turner</surname><given-names>S.W.</given-names></name><name><surname>Freudenthal</surname><given-names>J.</given-names></name><name><surname>Roitman</surname><given-names>D.B.</given-names></name></person-group>
<article-title>Improved fabrication of zero-mode waveguides for single-molecule detection</article-title>
<source>J. Appl. Phys.</source>
<year>2008</year>
<volume>103</volume>
<fpage>034301</fpage>
<pub-id pub-id-type="doi">10.1063/1.2831366</pub-id>
</element-citation></ref><ref id="B117-ijms-17-01555"><label>117.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>H.-C.</given-names></name><name><surname>Jayasinghe</surname><given-names>L.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Reid</surname><given-names>S.</given-names></name><name><surname>Bayley</surname><given-names>H.</given-names></name></person-group>
<article-title>Continuous base identification for single-molecule nanopore DNA sequencing</article-title>
<source>Nat. Nanotechnol.</source>
<year>2009</year>
<volume>4</volume>
<fpage>265</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1038/nnano.2009.12</pub-id>
<?supplied-pmid 19350039?><pub-id pub-id-type="pmid">19350039</pub-id></element-citation></ref><ref id="B118-ijms-17-01555"><label>118.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vinaixa</surname><given-names>M.</given-names></name><name><surname>Schymanski</surname><given-names>E.L.</given-names></name><name><surname>Neumann</surname><given-names>S.</given-names></name><name><surname>Navarro</surname><given-names>M.</given-names></name><name><surname>Salek</surname><given-names>R.M.</given-names></name><name><surname>Yanes</surname><given-names>O.</given-names></name></person-group>
<article-title>Mass spectral databases for LC/MS- and GC/MS-based metabolomics: State of the field and future prospects</article-title>
<source>TrAC Trends Anal. Chem.</source>
<year>2016</year>
<volume>78</volume>
<fpage>23</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/j.trac.2015.09.005</pub-id>
</element-citation></ref><ref id="B119-ijms-17-01555"><label>119.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Candille</surname><given-names>S.I.</given-names></name><name><surname>Choi</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Li-Pook-Than</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Snyder</surname><given-names>M.</given-names></name></person-group>
<article-title>Variation and genetic control of protein abundance in humans</article-title>
<source>Nature</source>
<year>2013</year>
<volume>499</volume>
<fpage>79</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1038/nature12223</pub-id>
<?supplied-pmid 23676674?><pub-id pub-id-type="pmid">23676674</pub-id></element-citation></ref><ref id="B120-ijms-17-01555"><label>120.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vogel</surname><given-names>C.</given-names></name><name><surname>Marcotte</surname><given-names>E.M.</given-names></name></person-group>
<article-title>Insights into the regulation of protein abundance from proteomic and transcriptomic analyses</article-title>
<source>Nat. Rev. Genet.</source>
<year>2012</year>
<volume>13</volume>
<fpage>227</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3185</pub-id>
<?supplied-pmid 22411467?><pub-id pub-id-type="pmid">22411467</pub-id></element-citation></ref><ref id="B121-ijms-17-01555"><label>121.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bittremieux</surname><given-names>W.</given-names></name><name><surname>Valkenborg</surname><given-names>D.</given-names></name><name><surname>Martens</surname><given-names>L.</given-names></name><name><surname>Laukens</surname><given-names>K.</given-names></name></person-group>
<article-title>Computational quality control tools for mass spectrometry proteomics</article-title>
<source>Proteomics</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1002/pmic.201600159</pub-id>
<?supplied-pmid 27549080?><pub-id pub-id-type="pmid">27549080</pub-id></element-citation></ref><ref id="B122-ijms-17-01555"><label>122.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>E.W.</given-names></name><name><surname>Overall</surname><given-names>C.M.</given-names></name><name><surname>van Eyk</surname><given-names>J.E.</given-names></name><name><surname>Baker</surname><given-names>M.S.</given-names></name><name><surname>Paik</surname><given-names>Y.-K.</given-names></name><name><surname>Weintraub</surname><given-names>S.T.</given-names></name><name><surname>Lane</surname><given-names>L.</given-names></name><name><surname>Martens</surname><given-names>L.</given-names></name><name><surname>Vandenbrouck</surname><given-names>Y.</given-names></name><name><surname>Kusebauch</surname><given-names>U.</given-names></name><etal/></person-group>
<article-title>Human proteome project mass spectrometry data interpretation guidelines 2.1</article-title>
<source>J. Proteome Res.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00392</pub-id>
<?supplied-pmid 27490519?><pub-id pub-id-type="pmid">27490519</pub-id></element-citation></ref><ref id="B123-ijms-17-01555"><label>123.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whiteaker</surname><given-names>J.R.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Anderson</surname><given-names>L.</given-names></name><name><surname>Paulovich</surname><given-names>A.G.</given-names></name></person-group>
<article-title>An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers</article-title>
<source>Mol. Cell. Proteom.</source>
<year>2010</year>
<volume>9</volume>
<fpage>184</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1074/mcp.M900254-MCP200</pub-id>
<?supplied-pmid 19843560?><pub-id pub-id-type="pmid">19843560</pub-id></element-citation></ref><ref id="B124-ijms-17-01555"><label>124.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fehniger</surname><given-names>T.E.</given-names></name><name><surname>Boja</surname><given-names>E.S.</given-names></name><name><surname>Rodriguez</surname><given-names>H.</given-names></name><name><surname>Baker</surname><given-names>M.S.</given-names></name><name><surname>Marko-Varga</surname><given-names>G.</given-names></name></person-group>
<article-title>Four areas of engagement requiring strengthening in modern proteomics today</article-title>
<source>J. Proteome Res.</source>
<year>2014</year>
<volume>13</volume>
<fpage>5310</fpage>
<lpage>5318</lpage>
<pub-id pub-id-type="doi">10.1021/pr500472d</pub-id>
<?supplied-pmid 25405748?><pub-id pub-id-type="pmid">25405748</pub-id></element-citation></ref><ref id="B125-ijms-17-01555"><label>125.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Vongsangnak</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name></person-group>
<article-title>Evaluation and comparison of multiple aligners for next-generation sequencing data analysis</article-title>
<source>BioMed Res. Int.</source>
<year>2014</year>
<volume>2014</volume>
<fpage>309650</fpage>
<pub-id pub-id-type="doi">10.1155/2014/309650</pub-id>
<?supplied-pmid 24779008?><pub-id pub-id-type="pmid">24779008</pub-id></element-citation></ref><ref id="B126-ijms-17-01555"><label>126.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pabinger</surname><given-names>S.</given-names></name><name><surname>Dander</surname><given-names>A.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name><name><surname>Snajder</surname><given-names>R.</given-names></name><name><surname>Sperk</surname><given-names>M.</given-names></name><name><surname>Efremova</surname><given-names>M.</given-names></name><name><surname>Krabichler</surname><given-names>B.</given-names></name><name><surname>Speicher</surname><given-names>M.R.</given-names></name><name><surname>Zschocke</surname><given-names>J.</given-names></name><name><surname>Trajanoski</surname><given-names>Z.</given-names></name></person-group>
<article-title>A survey of tools for variant analysis of next-generation genome sequencing data</article-title>
<source>Brief. Bioinform.</source>
<year>2014</year>
<volume>15</volume>
<fpage>256</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1093/bib/bbs086</pub-id>
<?supplied-pmid 23341494?><pub-id pub-id-type="pmid">23341494</pub-id></element-citation></ref><ref id="B127-ijms-17-01555"><label>127.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evani</surname><given-names>U.S.</given-names></name><name><surname>Challis</surname><given-names>D.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Jackson</surname><given-names>A.R.</given-names></name><name><surname>Paithankar</surname><given-names>S.</given-names></name><name><surname>Bainbridge</surname><given-names>M.N.</given-names></name><name><surname>Jakkamsetti</surname><given-names>A.</given-names></name><name><surname>Pham</surname><given-names>P.</given-names></name><name><surname>Coarfa</surname><given-names>C.</given-names></name><name><surname>Milosavljevic</surname><given-names>A.</given-names></name></person-group>
<article-title>Atlas2 cloud: A framework for personal genome analysis in the cloud</article-title>
<source>BMC Genom.</source>
<year>2012</year>
<volume>13</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-13-S6-S19</pub-id>
<?supplied-pmid 23134663?><pub-id pub-id-type="pmid">23134663</pub-id></element-citation></ref><ref id="B128-ijms-17-01555"><label>128.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cibulskis</surname><given-names>K.</given-names></name><name><surname>Lawrence</surname><given-names>M.S.</given-names></name><name><surname>Carter</surname><given-names>S.L.</given-names></name><name><surname>Sivachenko</surname><given-names>A.</given-names></name><name><surname>Jaffe</surname><given-names>D.</given-names></name><name><surname>Sougnez</surname><given-names>C.</given-names></name><name><surname>Gabriel</surname><given-names>S.</given-names></name><name><surname>Meyerson</surname><given-names>M.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name></person-group>
<article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>
<source>Nat. Biotechnol.</source>
<year>2013</year>
<volume>31</volume>
<fpage>213</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id>
<?supplied-pmid 23396013?><pub-id pub-id-type="pmid">23396013</pub-id></element-citation></ref><ref id="B129-ijms-17-01555"><label>129.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koboldt</surname><given-names>D.C.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Larson</surname><given-names>D.E.</given-names></name><name><surname>Shen</surname><given-names>D.</given-names></name><name><surname>McLellan</surname><given-names>M.D.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Miller</surname><given-names>C.A.</given-names></name><name><surname>Mardis</surname><given-names>E.R.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Wilson</surname><given-names>R.K.</given-names></name></person-group>
<article-title>Varscan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing</article-title>
<source>Genome Res.</source>
<year>2012</year>
<volume>22</volume>
<fpage>568</fpage>
<lpage>576</lpage>
<pub-id pub-id-type="doi">10.1101/gr.129684.111</pub-id>
<?supplied-pmid 22300766?><pub-id pub-id-type="pmid">22300766</pub-id></element-citation></ref><ref id="B130-ijms-17-01555"><label>130.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A.</given-names></name><name><surname>Hanna</surname><given-names>M.</given-names></name><name><surname>Banks</surname><given-names>E.</given-names></name><name><surname>Sivachenko</surname><given-names>A.</given-names></name><name><surname>Cibulskis</surname><given-names>K.</given-names></name><name><surname>Kernytsky</surname><given-names>A.</given-names></name><name><surname>Garimella</surname><given-names>K.</given-names></name><name><surname>Altshuler</surname><given-names>D.</given-names></name><name><surname>Gabriel</surname><given-names>S.</given-names></name><name><surname>Daly</surname><given-names>M.</given-names></name></person-group>
<article-title>The genome analysis toolkit: A mapreduce framework for analyzing next-generation DNA sequencing data</article-title>
<source>Genome Res.</source>
<year>2010</year>
<volume>20</volume>
<fpage>1297</fpage>
<lpage>1303</lpage>
<pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
<?supplied-pmid 20644199?><pub-id pub-id-type="pmid">20644199</pub-id></element-citation></ref><ref id="B131-ijms-17-01555"><label>131.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spencer</surname><given-names>D.H.</given-names></name><name><surname>Tyagi</surname><given-names>M.</given-names></name><name><surname>Vallania</surname><given-names>F.</given-names></name><name><surname>Bredemeyer</surname><given-names>A.J.</given-names></name><name><surname>Pfeifer</surname><given-names>J.D.</given-names></name><name><surname>Mitra</surname><given-names>R.D.</given-names></name><name><surname>Duncavage</surname><given-names>E.J.</given-names></name></person-group>
<article-title>Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data</article-title>
<source>J. Mol. Diagn.</source>
<year>2014</year>
<volume>16</volume>
<fpage>75</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmoldx.2013.09.003</pub-id>
<?supplied-pmid 24211364?><pub-id pub-id-type="pmid">24211364</pub-id></element-citation></ref><ref id="B132-ijms-17-01555"><label>132.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manrai</surname><given-names>A.K.</given-names></name><name><surname>Funke</surname><given-names>B.H.</given-names></name><name><surname>Rehm</surname><given-names>H.L.</given-names></name><name><surname>Olesen</surname><given-names>M.S.</given-names></name><name><surname>Maron</surname><given-names>B.A.</given-names></name><name><surname>Szolovits</surname><given-names>P.</given-names></name><name><surname>Margulies</surname><given-names>D.M.</given-names></name><name><surname>Loscalzo</surname><given-names>J.</given-names></name><name><surname>Kohane</surname><given-names>I.S.</given-names></name></person-group>
<article-title>Genetic misdiagnoses and the potential for health disparities</article-title>
<source>N. Engl. J. Med.</source>
<year>2016</year>
<volume>375</volume>
<fpage>655</fpage>
<lpage>665</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMsa1507092</pub-id>
<?supplied-pmid 27532831?><pub-id pub-id-type="pmid">27532831</pub-id></element-citation></ref><ref id="B133-ijms-17-01555"><label>133.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gullapalli</surname><given-names>R.R.</given-names></name><name><surname>Desai</surname><given-names>K.V.</given-names></name><name><surname>Santana-Santos</surname><given-names>L.</given-names></name><name><surname>Kant</surname><given-names>J.A.</given-names></name><name><surname>Becich</surname><given-names>M.J.</given-names></name></person-group>
<article-title>Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics</article-title>
<source>J. Pathol. Inform.</source>
<year>2012</year>
<volume>3</volume>
<fpage>40</fpage>
<?supplied-pmid 23248761?><pub-id pub-id-type="pmid">23248761</pub-id></element-citation></ref><ref id="B134-ijms-17-01555"><label>134.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>E.W.</given-names></name></person-group>
<article-title>File formats commonly used in mass spectrometry proteomics</article-title>
<source>Mol. Cell. Proteom.</source>
<year>2012</year>
<volume>11</volume>
<fpage>1612</fpage>
<lpage>1621</lpage>
<pub-id pub-id-type="doi">10.1074/mcp.R112.019695</pub-id>
<?supplied-pmid 22956731?><pub-id pub-id-type="pmid">22956731</pub-id></element-citation></ref><ref id="B135-ijms-17-01555"><label>135.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Misra</surname><given-names>B.B.</given-names></name><name><surname>van der Hooft</surname><given-names>J.J.</given-names></name></person-group>
<article-title>Updates in metabolomics tools and resources: 2014&#x02013;2015</article-title>
<source>Electrophoresis</source>
<year>2016</year>
<volume>37</volume>
<fpage>86</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1002/elps.201500417</pub-id>
<?supplied-pmid 26464019?><pub-id pub-id-type="pmid">26464019</pub-id></element-citation></ref><ref id="B136-ijms-17-01555"><label>136.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Annesley</surname><given-names>T.</given-names></name><name><surname>Diamandis</surname><given-names>E.</given-names></name><name><surname>Bachmann</surname><given-names>L.</given-names></name><name><surname>Hanash</surname><given-names>S.</given-names></name><name><surname>Hart</surname><given-names>B.</given-names></name><name><surname>Javahery</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>R.</given-names></name></person-group>
<article-title>A spectrum of views on clinical mass spectrometry</article-title>
<source>Clin. Chem.</source>
<year>2016</year>
<volume>62</volume>
<fpage>30</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1373/clinchem.2015.250258</pub-id>
<?supplied-pmid 26553793?><pub-id pub-id-type="pmid">26553793</pub-id></element-citation></ref><ref id="B137-ijms-17-01555"><label>137.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lathrop</surname><given-names>J.T.</given-names></name><name><surname>Jeffery</surname><given-names>D.A.</given-names></name><name><surname>Shea</surname><given-names>Y.R.</given-names></name><name><surname>Scholl</surname><given-names>P.F.</given-names></name><name><surname>Chan</surname><given-names>M.M.</given-names></name></person-group>
<article-title>US food and drug administration perspectives on clinical mass spectrometry</article-title>
<source>Clin. Chem.</source>
<year>2016</year>
<volume>62</volume>
<fpage>41</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1373/clinchem.2015.244731</pub-id>
<?supplied-pmid 26553791?><pub-id pub-id-type="pmid">26553791</pub-id></element-citation></ref><ref id="B138-ijms-17-01555"><label>138.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Levin</surname><given-names>N.</given-names></name><name><surname>Salek</surname><given-names>R.M.</given-names></name><name><surname>Steinbeck</surname><given-names>C.</given-names></name></person-group>
<article-title>Chapter 11&#x02014;From databases to big data</article-title>
<source>Metabolic Phenotyping in Personalized and Public Healthcare</source>
<publisher-name>Academic Press</publisher-name>
<publisher-loc>Boston, MA, USA</publisher-loc>
<year>2016</year>
<fpage>317</fpage>
<lpage>331</lpage>
</element-citation></ref><ref id="B139-ijms-17-01555"><label>139.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group>
<article-title>The genotype-tissue expression (GTEX) pilot analysis: Multitissue gene regulation in humans</article-title>
<source>Science</source>
<year>2015</year>
<volume>348</volume>
<fpage>648</fpage>
<lpage>660</lpage>
<pub-id pub-id-type="pmid">25954001</pub-id></element-citation></ref><ref id="B140-ijms-17-01555"><label>140.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torell</surname><given-names>F.</given-names></name><name><surname>Bennett</surname><given-names>K.</given-names></name><name><surname>Cereghini</surname><given-names>S.</given-names></name><name><surname>Rannar</surname><given-names>S.</given-names></name><name><surname>Lundstedt-Enkel</surname><given-names>K.</given-names></name><name><surname>Moritz</surname><given-names>T.</given-names></name><name><surname>Haumaitre</surname><given-names>C.</given-names></name><name><surname>Trygg</surname><given-names>J.</given-names></name><name><surname>Lundstedt</surname><given-names>T.</given-names></name></person-group>
<article-title>Multi-organ contribution to the metabolic plasma profile using hierarchical modelling</article-title>
<source>PLoS ONE</source>
<year>2015</year>
<volume>10</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0129260</pub-id>
<?supplied-pmid 26086868?><pub-id pub-id-type="pmid">26086868</pub-id></element-citation></ref><ref id="B141-ijms-17-01555"><label>141.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Do</surname><given-names>K.T.</given-names></name><name><surname>Kastenm&#x000fc;ller</surname><given-names>G.</given-names></name><name><surname>Mook-Kanamori</surname><given-names>D.O.</given-names></name><name><surname>Yousri</surname><given-names>N.A.</given-names></name><name><surname>Theis</surname><given-names>F.J.</given-names></name><name><surname>Suhre</surname><given-names>K.</given-names></name><name><surname>Krumsiek</surname><given-names>J.</given-names></name></person-group>
<article-title>Network-based approach for analyzing intra- and interfluid metabolite associations in human blood, urine, and saliva</article-title>
<source>J. Proteome Res.</source>
<year>2015</year>
<volume>14</volume>
<fpage>1183</fpage>
<lpage>1194</lpage>
<pub-id pub-id-type="doi">10.1021/pr501130a</pub-id>
<?supplied-pmid 25434815?><pub-id pub-id-type="pmid">25434815</pub-id></element-citation></ref><ref id="B142-ijms-17-01555"><label>142.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGregor</surname><given-names>K.</given-names></name><name><surname>Bernatsky</surname><given-names>S.</given-names></name><name><surname>Colmegna</surname><given-names>I.</given-names></name><name><surname>Hudson</surname><given-names>M.</given-names></name><name><surname>Pastinen</surname><given-names>T.</given-names></name><name><surname>Labbe</surname><given-names>A.</given-names></name><name><surname>Greenwood</surname><given-names>C.M.T.</given-names></name></person-group>
<article-title>An evaluation of methods correcting for cell-type heterogeneity in DNA methylation studies</article-title>
<source>Genome Biol.</source>
<year>2016</year>
<volume>17</volume>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1186/s13059-016-0935-y</pub-id>
<?supplied-pmid 27142380?><pub-id pub-id-type="pmid">26753840</pub-id></element-citation></ref><ref id="B143-ijms-17-01555"><label>143.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buettner</surname><given-names>F.</given-names></name><name><surname>Natarajan</surname><given-names>K.N.</given-names></name><name><surname>Casale</surname><given-names>F.P.</given-names></name><name><surname>Proserpio</surname><given-names>V.</given-names></name><name><surname>Scialdone</surname><given-names>A.</given-names></name><name><surname>Theis</surname><given-names>F.J.</given-names></name><name><surname>Teichmann</surname><given-names>S.A.</given-names></name><name><surname>Marioni</surname><given-names>J.C.</given-names></name><name><surname>Stegle</surname><given-names>O.</given-names></name></person-group>
<article-title>Computational analysis of cell-to-cell heterogeneity in single-cell RNA-Sequencing data reveals hidden subpopulations of cells</article-title>
<source>Nat. Biotechnol.</source>
<year>2015</year>
<volume>33</volume>
<fpage>155</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3102</pub-id>
<?supplied-pmid 25599176?><pub-id pub-id-type="pmid">25599176</pub-id></element-citation></ref><ref id="B144-ijms-17-01555"><label>144.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Houseman</surname><given-names>E.A.</given-names></name><name><surname>Molitor</surname><given-names>J.</given-names></name><name><surname>Marsit</surname><given-names>C.J.</given-names></name></person-group>
<article-title>Reference-free cell mixture adjustments in analysis of DNA methylation data</article-title>
<source>Bioinformatics</source>
<year>2014</year>
<volume>30</volume>
<fpage>1431</fpage>
<lpage>1439</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btu029</pub-id>
<?supplied-pmid 24451622?><pub-id pub-id-type="pmid">24451622</pub-id></element-citation></ref><ref id="B145-ijms-17-01555"><label>145.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bock</surname><given-names>C.</given-names></name><name><surname>Farlik</surname><given-names>M.</given-names></name><name><surname>Sheffield</surname><given-names>N.C.</given-names></name></person-group>
<article-title>Multi-omics of single cells: Strategies and applications</article-title>
<source>Trends Biotechnol.</source>
<year>2016</year>
<volume>34</volume>
<fpage>605</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="doi">10.1016/j.tibtech.2016.04.004</pub-id>
<?supplied-pmid 27212022?><pub-id pub-id-type="pmid">27212022</pub-id></element-citation></ref><ref id="B146-ijms-17-01555"><label>146.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><collab>Biomarkers Definitions Working Group</collab></person-group>
<article-title>Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework</article-title>
<source>Clin. Pharmacol. Ther.</source>
<year>2001</year>
<volume>69</volume>
<fpage>89</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">11240971</pub-id></element-citation></ref><ref id="B147-ijms-17-01555"><label>147.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Halim</surname><given-names>A.-B.</given-names></name></person-group>
<source>Biomarkers in Drug Development: A Useful Tool but Discrepant Results May Have a Major Impact</source>
<publisher-name>INTECH Open Access Publisher</publisher-name>
<publisher-loc>Rijeka, Croatia</publisher-loc>
<year>2011</year>
</element-citation></ref><ref id="B148-ijms-17-01555"><label>148.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Micheel</surname><given-names>C.M.</given-names></name><name><surname>Nass</surname><given-names>S.J.</given-names></name><name><surname>Omenn</surname><given-names>G.S.</given-names></name></person-group>
<source>Evolution of Translational Omics: Lessons Learned and the Path Forward</source>
<publisher-name>National Academies Press</publisher-name>
<publisher-loc>Washington, DC, USA</publisher-loc>
<year>2012</year>
</element-citation></ref><ref id="B149-ijms-17-01555"><label>149.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feuerstein</surname><given-names>G.</given-names></name><name><surname>Dormer</surname><given-names>C.</given-names></name><name><surname>Ruffolo</surname><given-names>R.</given-names></name><name><surname>Stiles</surname><given-names>G.</given-names></name><name><surname>Walsh</surname><given-names>F.</given-names></name><name><surname>Rutkowski</surname><given-names>J.</given-names></name></person-group>
<article-title>Translational medicine perspectives of biomarkers in drug discovery and development. Part I. Target selection and validation-biomarkers take center stage</article-title>
<source>Int. Drug Discov.</source>
<year>2007</year>
<volume>2</volume>
<fpage>36</fpage>
<lpage>43</lpage>
</element-citation></ref><ref id="B150-ijms-17-01555"><label>150.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Br&#x000fc;nner</surname><given-names>N.</given-names></name></person-group>
<article-title>What is the difference between &#x0201c;predictive and prognostic biomarkers&#x0201d;? Can you give some examples</article-title>
<source>Connection</source>
<year>2009</year>
<volume>13</volume>
<fpage>18</fpage>
</element-citation></ref><ref id="B151-ijms-17-01555"><label>151.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frank</surname><given-names>R.</given-names></name><name><surname>Hargreaves</surname><given-names>R.</given-names></name></person-group>
<article-title>Clinical biomarkers in drug discovery and development</article-title>
<source>Nat. Rev. Drug Discov.</source>
<year>2003</year>
<volume>2</volume>
<fpage>566</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1130</pub-id>
<?supplied-pmid 12838269?><pub-id pub-id-type="pmid">12838269</pub-id></element-citation></ref><ref id="B152-ijms-17-01555"><label>152.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horvath</surname><given-names>A.R.</given-names></name><name><surname>Lord</surname><given-names>S.J.</given-names></name><name><surname>StJohn</surname><given-names>A.</given-names></name><name><surname>Sandberg</surname><given-names>S.</given-names></name><name><surname>Cobbaert</surname><given-names>C.M.</given-names></name><name><surname>Lorenz</surname><given-names>S.</given-names></name><name><surname>Monaghan</surname><given-names>P.J.</given-names></name><name><surname>Verhagen-Kamerbeek</surname><given-names>W.D.J.</given-names></name><name><surname>Ebert</surname><given-names>C.</given-names></name><name><surname>Bossuyt</surname><given-names>P.M.M.</given-names></name></person-group>
<article-title>From biomarkers to medical tests: The changing landscape of test evaluation</article-title>
<source>Clin. Chim. Acta</source>
<year>2014</year>
<volume>427</volume>
<fpage>49</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/j.cca.2013.09.018</pub-id>
<?supplied-pmid 24076255?><pub-id pub-id-type="pmid">24076255</pub-id></element-citation></ref><ref id="B153-ijms-17-01555"><label>153.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotelling</surname><given-names>H.</given-names></name></person-group>
<article-title>Analysis of a complex of statistical variables into principal components</article-title>
<source>J. Educ. Psychol.</source>
<year>1933</year>
<volume>24</volume>
<fpage>417</fpage>
<pub-id pub-id-type="doi">10.1037/h0071325</pub-id>
</element-citation></ref><ref id="B154-ijms-17-01555"><label>154.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rutledge</surname><given-names>D.N.</given-names></name><name><surname>Bouveresse</surname><given-names>D.J.-R.</given-names></name></person-group>
<article-title>Independent components analysis with the jade algorithm</article-title>
<source>TrAC Trends Anal. Chem.</source>
<year>2013</year>
<volume>50</volume>
<fpage>22</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.trac.2013.03.013</pub-id>
</element-citation></ref><ref id="B155-ijms-17-01555"><label>155.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartigan</surname><given-names>J.A.</given-names></name><name><surname>Wong</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Algorithm as 136: A k-means clustering algorithm</article-title>
<source>J. R. Stat. Soc. Ser. C</source>
<year>1979</year>
<volume>28</volume>
<fpage>100</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.2307/2346830</pub-id>
</element-citation></ref><ref id="B156-ijms-17-01555"><label>156.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>S.C.</given-names></name></person-group>
<article-title>Hierarchical clustering schemes</article-title>
<source>Psychometrika</source>
<year>1967</year>
<volume>32</volume>
<fpage>241</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1007/BF02289588</pub-id>
<?supplied-pmid 5234703?><pub-id pub-id-type="pmid">5234703</pub-id></element-citation></ref><ref id="B157-ijms-17-01555"><label>157.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohonen</surname><given-names>T.</given-names></name></person-group>
<article-title>The self-organizing map</article-title>
<source>Proc. IEEE</source>
<year>1990</year>
<volume>78</volume>
<fpage>1464</fpage>
<lpage>1480</lpage>
<pub-id pub-id-type="doi">10.1109/5.58325</pub-id>
</element-citation></ref><ref id="B158-ijms-17-01555"><label>158.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wold</surname><given-names>S.</given-names></name><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>M.</given-names></name><name><surname>Eriksson</surname><given-names>L.</given-names></name></person-group>
<article-title>Pls-regression: A basic tool of chemometrics</article-title>
<source>Chemom. Intell. Lab. Syst.</source>
<year>2001</year>
<volume>58</volume>
<fpage>109</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/S0169-7439(01)00155-1</pub-id>
</element-citation></ref><ref id="B159-ijms-17-01555"><label>159.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trygg</surname><given-names>J.</given-names></name><name><surname>Wold</surname><given-names>S.</given-names></name></person-group>
<article-title>Orthogonal projections to latent structures (O-PLS)</article-title>
<source>J. Chemom.</source>
<year>2002</year>
<volume>16</volume>
<fpage>119</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1002/cem.695</pub-id>
</element-citation></ref><ref id="B160-ijms-17-01555"><label>160.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cortes</surname><given-names>C.</given-names></name><name><surname>Vapnik</surname><given-names>V.</given-names></name></person-group>
<article-title>Support-vector networks</article-title>
<source>Mach. Learn.</source>
<year>1995</year>
<volume>20</volume>
<fpage>273</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1007/BF00994018</pub-id>
</element-citation></ref><ref id="B161-ijms-17-01555"><label>161.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McShane</surname><given-names>L.M.</given-names></name><name><surname>Cavenagh</surname><given-names>M.M.</given-names></name><name><surname>Lively</surname><given-names>T.G.</given-names></name><name><surname>Eberhard</surname><given-names>D.A.</given-names></name><name><surname>Bigbee</surname><given-names>W.L.</given-names></name><name><surname>Williams</surname><given-names>P.M.</given-names></name><name><surname>Mesirov</surname><given-names>J.P.</given-names></name><name><surname>Polley</surname><given-names>M.-Y.C.</given-names></name><name><surname>Kim</surname><given-names>K.Y.</given-names></name><name><surname>Tricoli</surname><given-names>J.V.</given-names></name><etal/></person-group>
<article-title>Criteria for the use of omics-based predictors in clinical trials</article-title>
<source>Nature</source>
<year>2013</year>
<volume>502</volume>
<fpage>317</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1038/nature12564</pub-id>
<?supplied-pmid 24132288?><pub-id pub-id-type="pmid">24132288</pub-id></element-citation></ref><ref id="B162-ijms-17-01555"><label>162.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Satagopam</surname><given-names>V.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Eifes</surname><given-names>S.</given-names></name><name><surname>Gawron</surname><given-names>P.</given-names></name><name><surname>Ostaszewski</surname><given-names>M.</given-names></name><name><surname>Gebel</surname><given-names>S.</given-names></name><name><surname>Barbosa-Silva</surname><given-names>A.</given-names></name><name><surname>Balling</surname><given-names>R.</given-names></name><name><surname>Schneider</surname><given-names>R.</given-names></name></person-group>
<article-title>Integration and visualization of translational medicine data for better understanding of human diseases</article-title>
<source>Big Data</source>
<year>2016</year>
<volume>4</volume>
<fpage>97</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1089/big.2015.0057</pub-id>
<?supplied-pmid 27441714?><pub-id pub-id-type="pmid">27441714</pub-id></element-citation></ref><ref id="B163-ijms-17-01555"><label>163.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Offroy</surname><given-names>M.</given-names></name><name><surname>Duponchel</surname><given-names>L.</given-names></name></person-group>
<article-title>Topological data analysis: A promising big data exploration tool in biology, analytical chemistry and physical chemistry</article-title>
<source>Anal. Chim. Acta</source>
<year>2016</year>
<volume>910</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1016/j.aca.2015.12.037</pub-id>
<?supplied-pmid 26873463?><pub-id pub-id-type="pmid">26873463</pub-id></element-citation></ref><ref id="B164-ijms-17-01555"><label>164.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lum</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Lehman</surname><given-names>A.</given-names></name><name><surname>Ishkanov</surname><given-names>T.</given-names></name><name><surname>Vejdemo-Johansson</surname><given-names>M.</given-names></name><name><surname>Alagappan</surname><given-names>M.</given-names></name><name><surname>Carlsson</surname><given-names>J.</given-names></name><name><surname>Carlsson</surname><given-names>G.</given-names></name></person-group>
<article-title>Extracting insights from the shape of complex data using topology</article-title>
<source>Sci. Rep.</source>
<year>2013</year>
<volume>3</volume>
<fpage>1236</fpage>
<pub-id pub-id-type="doi">10.1038/srep01236</pub-id>
<?supplied-pmid 23393618?><pub-id pub-id-type="pmid">23393618</pub-id></element-citation></ref><ref id="B165-ijms-17-01555"><label>165.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>G.</given-names></name></person-group>
<article-title>Topology and data</article-title>
<source>Bull. Am. Math. Soc.</source>
<year>2009</year>
<volume>46</volume>
<fpage>255</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1090/S0273-0979-09-01249-X</pub-id>
</element-citation></ref><ref id="B166-ijms-17-01555"><label>166.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nielson</surname><given-names>J.L.</given-names></name><name><surname>Paquette</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>A.W.</given-names></name><name><surname>Guandique</surname><given-names>C.F.</given-names></name><name><surname>Tovar</surname><given-names>C.A.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Irvine</surname><given-names>K.-A.</given-names></name><name><surname>Gensel</surname><given-names>J.C.</given-names></name><name><surname>Kloke</surname><given-names>J.</given-names></name><name><surname>Petrossian</surname><given-names>T.C.</given-names></name><etal/></person-group>
<article-title>Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury</article-title>
<source>Nat. Commun.</source>
<year>2015</year>
<volume>6</volume>
<fpage>8581</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms9581</pub-id>
<?supplied-pmid 26466022?><pub-id pub-id-type="pmid">26466022</pub-id></element-citation></ref><ref id="B167-ijms-17-01555"><label>167.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salazar</surname><given-names>J.</given-names></name><name><surname>Amri</surname><given-names>H.</given-names></name><name><surname>Noursi</surname><given-names>D.</given-names></name><name><surname>Abu-Asab</surname><given-names>M.</given-names></name></person-group>
<article-title>Computational tools for parsimony phylogenetic analysis of omics data</article-title>
<source>Omics J. Integr. Biol.</source>
<year>2015</year>
<volume>19</volume>
<fpage>471</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1089/omi.2015.0018</pub-id>
<?supplied-pmid 26230532?><pub-id pub-id-type="pmid">26230532</pub-id></element-citation></ref><ref id="B168-ijms-17-01555"><label>168.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altman</surname><given-names>R.B.</given-names></name><name><surname>Khuri</surname><given-names>N.</given-names></name><name><surname>Salit</surname><given-names>M.</given-names></name><name><surname>Giacomini</surname><given-names>K.M.</given-names></name></person-group>
<article-title>Unmet needs: Research helps regulators do their jobs</article-title>
<source>Sci. Transl. Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>315ps22</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aac4369</pub-id>
<?supplied-pmid 26606966?><pub-id pub-id-type="pmid">26606966</pub-id></element-citation></ref><ref id="B169-ijms-17-01555"><label>169.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zerhouni</surname><given-names>E.</given-names></name><name><surname>Hamburg</surname><given-names>M.</given-names></name></person-group>
<article-title>The need for global regulatory harmonization: A public health imperative</article-title>
<source>Sci. Transl. Med.</source>
<year>2016</year>
<volume>8</volume>
<fpage>338ed6</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaf1396</pub-id>
<?supplied-pmid 27169801?><pub-id pub-id-type="pmid">27169801</pub-id></element-citation></ref><ref id="B170-ijms-17-01555"><label>170.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Malin</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Ohno-Machado</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name></person-group>
<article-title>A community assessment of privacy preserving techniques for human genomes</article-title>
<source>BMC Med. Inform. Decis. Mak.</source>
<year>2014</year>
<volume>14</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1186/1472-6947-14-S1-S1</pub-id>
<?supplied-pmid 25521230?><pub-id pub-id-type="pmid">24387627</pub-id></element-citation></ref><ref id="B171-ijms-17-01555"><label>171.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shoenbill</surname><given-names>K.</given-names></name><name><surname>Fost</surname><given-names>N.</given-names></name><name><surname>Tachinardi</surname><given-names>U.</given-names></name><name><surname>Mendonca</surname><given-names>E.A.</given-names></name></person-group>
<article-title>Genetic data and electronic health records: A discussion of ethical, logistical and technological considerations</article-title>
<source>J. Am. Med. Inform. Assoc.</source>
<year>2014</year>
<volume>21</volume>
<fpage>171</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1136/amiajnl-2013-001694</pub-id>
<?supplied-pmid 23771953?><pub-id pub-id-type="pmid">23771953</pub-id></element-citation></ref><ref id="B172-ijms-17-01555"><label>172.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poste</surname><given-names>G.</given-names></name></person-group>
<article-title>Bring on the biomarkers</article-title>
<source>Nature</source>
<year>2011</year>
<volume>469</volume>
<fpage>156</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1038/469156a</pub-id>
<?supplied-pmid 21228852?><pub-id pub-id-type="pmid">21228852</pub-id></element-citation></ref><ref id="B173-ijms-17-01555"><label>173.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gligorijevic</surname><given-names>V.</given-names></name><name><surname>Malod-Dognin</surname><given-names>N.</given-names></name><name><surname>Przulj</surname><given-names>N.</given-names></name></person-group>
<article-title>Integrative methods for analyzing big data in precision medicine</article-title>
<source>Proteomics</source>
<year>2016</year>
<volume>16</volume>
<fpage>741</fpage>
<lpage>758</lpage>
<pub-id pub-id-type="doi">10.1002/pmic.201500396</pub-id>
<?supplied-pmid 26677817?><pub-id pub-id-type="pmid">26677817</pub-id></element-citation></ref><ref id="B174-ijms-17-01555"><label>174.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>W.Y.</given-names></name><name><surname>Glicksberg</surname><given-names>B.S.</given-names></name><name><surname>Gottesman</surname><given-names>O.</given-names></name><name><surname>Tamler</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Bottinger</surname><given-names>E.P.</given-names></name><name><surname>Dudley</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Identification of type 2 diabetes subgroups through topological analysis of patient similarity</article-title>
<source>Sci. Transl. Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>311ra174</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa9364</pub-id>
<?supplied-pmid 26511511?><pub-id pub-id-type="pmid">26511511</pub-id></element-citation></ref><ref id="B175-ijms-17-01555"><label>175.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asai</surname><given-names>Y.</given-names></name><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Oka</surname><given-names>H.</given-names></name><name><surname>Nomura</surname><given-names>T.</given-names></name><name><surname>Kitano</surname><given-names>H.</given-names></name></person-group>
<article-title>Databases for multilevel biophysiology research available at physiome.jp</article-title>
<source>Front. Physiol.</source>
<year>2015</year>
<volume>6</volume>
<fpage>251</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2015.00251</pub-id>
<?supplied-pmid 26441671?><pub-id pub-id-type="pmid">26441671</pub-id></element-citation></ref><ref id="B176-ijms-17-01555"><label>176.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garny</surname><given-names>A.</given-names></name><name><surname>Cooper</surname><given-names>J.</given-names></name><name><surname>Hunter</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Toward a VPH/physiome toolkit</article-title>
<source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source>
<year>2010</year>
<volume>2</volume>
<fpage>134</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1002/wsbm.63</pub-id>
<?supplied-pmid 20836018?><pub-id pub-id-type="pmid">20836018</pub-id></element-citation></ref><ref id="B177-ijms-17-01555"><label>177.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clancy</surname><given-names>C.E.</given-names></name><name><surname>An</surname><given-names>G.</given-names></name><name><surname>Cannon</surname><given-names>W.R.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>May</surname><given-names>E.E.</given-names></name><name><surname>Ortoleva</surname><given-names>P.</given-names></name><name><surname>Popel</surname><given-names>A.S.</given-names></name><name><surname>Sluka</surname><given-names>J.P.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Vicini</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>Multiscale modeling in the clinic: Drug design and development</article-title>
<source>Ann. Biomed. Eng.</source>
<year>2016</year>
<volume>44</volume>
<fpage>2591</fpage>
<lpage>2610</lpage>
<pub-id pub-id-type="doi">10.1007/s10439-016-1563-0</pub-id>
<?supplied-pmid 26885640?><pub-id pub-id-type="pmid">26885640</pub-id></element-citation></ref><ref id="B178-ijms-17-01555"><label>178.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henricks</surname><given-names>W.H.</given-names></name><name><surname>Karcher</surname><given-names>D.S.</given-names></name><name><surname>Harrison</surname><given-names>J.H.</given-names></name><name><surname>Sinard</surname><given-names>J.H.</given-names></name><name><surname>Riben</surname><given-names>M.W.</given-names></name><name><surname>Boyer</surname><given-names>P.J.</given-names></name><name><surname>Plath</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>A.</given-names></name><name><surname>Pantanowitz</surname><given-names>L.</given-names></name></person-group>
<article-title>Pathology informatics essentials for residents: A flexible informatics curriculum linked to accreditation council for graduate medical education milestones</article-title>
<source>J. Pathol. Inform.</source>
<year>2016</year>
<volume>7</volume>
<fpage>27</fpage>
<?supplied-pmid 27563486?><pub-id pub-id-type="pmid">27563486</pub-id></element-citation></ref><ref id="B179-ijms-17-01555"><label>179.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Louis</surname><given-names>D.N.</given-names></name><name><surname>Feldman</surname><given-names>M.</given-names></name><name><surname>Carter</surname><given-names>A.B.</given-names></name><name><surname>Dighe</surname><given-names>A.S.</given-names></name><name><surname>Pfeifer</surname><given-names>J.D.</given-names></name><name><surname>Bry</surname><given-names>L.</given-names></name><name><surname>Almeida</surname><given-names>J.S.</given-names></name><name><surname>Saltz</surname><given-names>J.</given-names></name><name><surname>Braun</surname><given-names>J.</given-names></name><name><surname>Tomaszewski</surname><given-names>J.E.</given-names></name></person-group>
<article-title>Computational pathology: A path ahead</article-title>
<source>Arch. Pathol. Lab. Med.</source>
<year>2015</year>
<volume>140</volume>
<fpage>41</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.5858/arpa.2015-0093-SA</pub-id>
<?supplied-pmid 26098131?><pub-id pub-id-type="pmid">26098131</pub-id></element-citation></ref><ref id="B180-ijms-17-01555"><label>180.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Louis</surname><given-names>D.N.</given-names></name><name><surname>Gerber</surname><given-names>G.K.</given-names></name><name><surname>Baron</surname><given-names>J.M.</given-names></name><name><surname>Bry</surname><given-names>L.</given-names></name><name><surname>Dighe</surname><given-names>A.S.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name><name><surname>Higgins</surname><given-names>J.M.</given-names></name><name><surname>Kuo</surname><given-names>F.C.</given-names></name><name><surname>Lane</surname><given-names>W.J.</given-names></name><name><surname>Michaelson</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Computational pathology: An emerging definition</article-title>
<source>Arch. Pathol. Lab. Med.</source>
<year>2014</year>
<volume>138</volume>
<fpage>1133</fpage>
<lpage>1138</lpage>
<pub-id pub-id-type="doi">10.5858/arpa.2014-0034-ED</pub-id>
<?supplied-pmid 25171694?><pub-id pub-id-type="pmid">25171694</pub-id></element-citation></ref><ref id="B181-ijms-17-01555"><label>181.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sirintrapun</surname><given-names>S.J.</given-names></name><name><surname>Zehir</surname><given-names>A.</given-names></name><name><surname>Syed</surname><given-names>A.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Schultz</surname><given-names>N.</given-names></name><name><surname>Cheng</surname><given-names>D.T.</given-names></name></person-group>
<article-title>Translational bioinformatics and clinical research (biomedical) informatics</article-title>
<source>Clin. Lab. Med.</source>
<year>2016</year>
<volume>36</volume>
<fpage>153</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.cll.2015.09.013</pub-id>
<?supplied-pmid 26851671?><pub-id pub-id-type="pmid">26851671</pub-id></element-citation></ref><ref id="B182-ijms-17-01555"><label>182.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miotto</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kidd</surname><given-names>B.A.</given-names></name><name><surname>Dudley</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Deep patient: An unsupervised representation to predict the future of patients from the electronic health records</article-title>
<source>Sci. Rep.</source>
<year>2016</year>
<volume>6</volume>
<fpage>26094</fpage>
<pub-id pub-id-type="doi">10.1038/srep26094</pub-id>
<?supplied-pmid 27185194?><pub-id pub-id-type="pmid">27185194</pub-id></element-citation></ref><ref id="B183-ijms-17-01555"><label>183.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soualmia</surname><given-names>L.F.</given-names></name><name><surname>Lecroq</surname><given-names>T.</given-names></name></person-group>
<article-title>Bioinformatics methods and tools to advance clinical care. Findings from the yearbook 2015 section on bioinformatics and translational informatics</article-title>
<source>Yearb. Med. Inform.</source>
<year>2015</year>
<volume>10</volume>
<fpage>170</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.15265/IY-2015-026</pub-id>
<?supplied-pmid 26293864?><pub-id pub-id-type="pmid">26293864</pub-id></element-citation></ref><ref id="B184-ijms-17-01555"><label>184.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tenenbaum</surname><given-names>J.D.</given-names></name><name><surname>Avillach</surname><given-names>P.</given-names></name><name><surname>Benham-Hutchins</surname><given-names>M.</given-names></name><name><surname>Breitenstein</surname><given-names>M.K.</given-names></name><name><surname>Crowgey</surname><given-names>E.L.</given-names></name><name><surname>Hoffman</surname><given-names>M.A.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Madhavan</surname><given-names>S.</given-names></name><name><surname>Mattison</surname><given-names>J.E.</given-names></name><name><surname>Nagarajan</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>An informatics research agenda to support precision medicine: Seven key areas</article-title>
<source>JAMIA</source>
<year>2016</year>
<volume>23</volume>
<fpage>791</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1093/jamia/ocv213</pub-id>
<?supplied-pmid 27107452?><pub-id pub-id-type="pmid">27107452</pub-id></element-citation></ref><ref id="B185-ijms-17-01555"><label>185.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altman</surname><given-names>R.B.</given-names></name><name><surname>Prabhu</surname><given-names>S.</given-names></name><name><surname>Sidow</surname><given-names>A.</given-names></name><name><surname>Zook</surname><given-names>J.M.</given-names></name><name><surname>Goldfeder</surname><given-names>R.</given-names></name><name><surname>Litwack</surname><given-names>D.</given-names></name><name><surname>Ashley</surname><given-names>E.</given-names></name><name><surname>Asimenos</surname><given-names>G.</given-names></name><name><surname>Bustamante</surname><given-names>C.D.</given-names></name><name><surname>Donigan</surname><given-names>K.</given-names></name><etal/></person-group>
<article-title>A research roadmap for next-generation sequencing informatics</article-title>
<source>Sci. Transl. Med.</source>
<year>2016</year>
<volume>8</volume>
<fpage>335ps310</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaf7314</pub-id>
<?supplied-pmid 27099173?><pub-id pub-id-type="pmid">27099173</pub-id></element-citation></ref><ref id="B186-ijms-17-01555"><label>186.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sahoo</surname><given-names>S.</given-names></name><name><surname>Franzson</surname><given-names>L.</given-names></name><name><surname>Jonsson</surname><given-names>J.J.</given-names></name><name><surname>Thiele</surname><given-names>I.</given-names></name></person-group>
<article-title>A compendium of inborn errors of metabolism mapped onto the human metabolic network</article-title>
<source>Mol. BioSyst.</source>
<year>2012</year>
<volume>8</volume>
<fpage>2545</fpage>
<lpage>2558</lpage>
<pub-id pub-id-type="doi">10.1039/c2mb25075f</pub-id>
<?supplied-pmid 22699794?><pub-id pub-id-type="pmid">22699794</pub-id></element-citation></ref><ref id="B187-ijms-17-01555"><label>187.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>D.-Y.</given-names></name><name><surname>Kim</surname><given-names>Y.-A.</given-names></name><name><surname>Przytycka</surname><given-names>T.M.</given-names></name></person-group>
<article-title>Chapter 5: Network biology approach to complex diseases</article-title>
<source>PLoS Comput. Biol.</source>
<year>2012</year>
<volume>8</volume>
<elocation-id>1555</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1002820</pub-id>
<?supplied-pmid 23300411?><pub-id pub-id-type="pmid">23300411</pub-id></element-citation></ref><ref id="B188-ijms-17-01555"><label>188.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hood</surname><given-names>L.</given-names></name><name><surname>Balling</surname><given-names>R.</given-names></name><name><surname>Auffray</surname><given-names>C.</given-names></name></person-group>
<article-title>Revolutionizing medicine in the 21st century through systems approaches</article-title>
<source>Biotechnol. J.</source>
<year>2012</year>
<volume>7</volume>
<fpage>992</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="doi">10.1002/biot.201100306</pub-id>
<?supplied-pmid 22815171?><pub-id pub-id-type="pmid">22815171</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-17-01555-f001" position="float"><label>Figure 1</label><caption><p>Multi-scale biology overview of systems medicine. Three main drivers define phenotype: (i) the molecular phenome, which is defined by the underlying molecular supports of biological information. The different omics strategies enable to interrogate these supports for information retrieval; (ii) environmental effects spanning from exposures to toxic substances or drugs to diet define the exposome; and (iii) the different clinical metrics used to define the clinical phenome. These different biological and clinical metrics should be approached in a multi-dimensional fashion and should take into account the inherent spatial and temporal scales of both measurement technologies and disease dynamics from the molecular to the population level.</p></caption><graphic xlink:href="ijms-17-01555-g001"/></fig><fig id="ijms-17-01555-f002" position="float"><label>Figure 2</label><caption><p>Schematic illustration of bioinformatics pipelines in next-generation sequencing (NGS) and mass spectrometry (MS)-based omics. <bold>Left</bold>: The NGS pipeline comprises library construction and capture, sequencing reaction, and signal processing. Then, a base-calling step is performed to define the unaligned nucleotide sequence. The data are stored in FASTAQ file format containing quality scores. Subsequently, read alignment to a reference sequence is performed, followed by variant calling and annotation. The final output is a list of variants in VCF format for visualization and interpretation; <bold>Right</bold>: MS pipeline starts with sample preparation, depending on the MS instruments and the combined separation method. Data acquisition is performed according to the chosen mode (full scan or tandem MS). Subsequently, a pre-processing step is needed for feature extraction and data cleaning. The result is a list of features that will undergo data analysis, molecular annotation, and identification before biological interpretation. Signal processing is platform-dependent in NGS; however, open source solutions are available for pre-processing MS data.</p></caption><graphic xlink:href="ijms-17-01555-g002"/></fig><fig id="ijms-17-01555-f003" position="float"><label>Figure 3</label><caption><p>Biomarker development pipeline milestones.</p></caption><graphic xlink:href="ijms-17-01555-g003"/></fig><fig id="ijms-17-01555-f004" position="float"><label>Figure 4</label><caption><p>Illustration of the two main machine learning techniques on which omics-based biomarker strategies rely. <bold>Left</bold>: All samples are unlabeled in unsupervised learning. A model separates samples into different clusters based on their biological similarity. A new sample (red circle) is classified according to its similarity to a particular cluster; <bold>Right</bold>: In supervised learning, a training dataset of samples with known class labels is used to build a model (blue circle for condition 1 and green circle for condition 2). The model maximizes the difference between samples from condition 1 and condition 2. Based on this learning, a label for a new sample (red circle) is determined.</p></caption><graphic xlink:href="ijms-17-01555-g004"/></fig><fig id="ijms-17-01555-f005" position="float"><label>Figure 5</label><caption><p>A stepwise approach to using machine learning methods for the prediction of clinical phenotypes. A training dataset is first collected. Then, a subset of features associated with the phenotype of interest is selected. Based on these features, a multi-variate model is built by the training data. A validation set acquired using the same omics profiling methods is collected and treated as new input to the established multi-variate model. The predictions provided by the model are used to assess the classification performance of the test input by comparing the model output and the actual clinical phenotypes of the patients in the validation set.</p></caption><graphic xlink:href="ijms-17-01555-g005"/></fig><fig id="ijms-17-01555-f006" position="float"><label>Figure 6</label><caption><p>Paradigm shift in Inborn Errors of Metabolism (IEM) diagnosis workflow. Laboratory workflow using high-throughput analytical technologies, integrative bioinformatics, and computational frameworks recovers molecular information for more effective medical decision-making.</p></caption><graphic xlink:href="ijms-17-01555-g006"/></fig></floats-group></article>